{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:44:03Z","timestamp":1793681043783,"version":"4.5.1"},"publisher-location":"New York, NY","reference-count":384,"publisher":"Springer US","isbn-type":[{"value":"9781071625729","type":"print"},{"value":"9781071625736","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2573-6_16","type":"book-chapter","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:06:13Z","timestamp":1662480373000},"page":"437-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacogenetics of Addiction Therapy"],"prefix":"10.1007","author":[{"given":"David P.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"11","key":"16_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/JOM.0000000000001157","volume":"59","author":"E Goplerud","year":"2017","unstructured":"Goplerud E, Hodge S, Benham T (2017) A substance use cost calculator for US employers with an emphasis on prescription pain medication misuse. J Occup Environ Med 59(11):1063\u20131071","journal-title":"J Occup Environ Med"},{"issue":"2","key":"16_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1520\/JFS2003221","volume":"49","author":"BC Wolf","year":"2004","unstructured":"Wolf BC, Lavezzi WA, Sullivan LM, Flannagan LM (2004) Methadone-related deaths in Palm Beach County. J Forensic Sci 49(2):375\u2013378","journal-title":"J Forensic Sci"},{"issue":"3","key":"16_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ajem.2009.11.008","volume":"29","author":"DL Zvosec","year":"2011","unstructured":"Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE (2011) Case series of 226 \u03b3-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 29(3):319\u2013332","journal-title":"Am J Emerg Med"},{"key":"16_CR4","first-page":"205","volume":"9","author":"RJ MacGowan","year":"1997","unstructured":"MacGowan RJ, Fichtner RR, Swanson N, Collier C, Kroliczak A, Cole G (1997) Factors associated with client-reported HIV infection among clients entering methadone treatment. AIDS Educ Prev 9:205\u2013217","journal-title":"AIDS Educ Prev"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0376-8716(94)90092-2","volume":"36","author":"B Meandzija","year":"1994","unstructured":"Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR (1994) HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 36:109\u2013113","journal-title":"Drug Alcohol Depend"},{"key":"16_CR6","unstructured":"The health consequences of smoking\u201450 years of progress: a report of the surgeon general (2014) US Dept. of Health and Human Services, Centers for Disease Control and Prevention, Atlanta. Accessed 10 Feb 2021"},{"key":"16_CR7","unstructured":"Centers for Disease Control and Prevention (CDC). Alcohol-Related Disease Impact (ARDI). CDC, Atlanta. April 2022"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"E109","DOI":"10.5888\/pcd11.130293","volume":"11","author":"M Stahre","year":"2014","unstructured":"Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X (2014) Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis 11:E109","journal-title":"Prev Chronic Dis"},{"issue":"4","key":"16_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.amepre.2017.12.021","volume":"54","author":"D Kanny","year":"2018","unstructured":"Kanny D, Naimi TS, Liu Y, Lu H, Brewer RD (2018) Annual Total binge drinks consumed by U.S. adults, 2015. Am J Prev Med 54(4):486\u2013496","journal-title":"Am J Prev Med"},{"key":"16_CR10","unstructured":"Substance Abuse and Mental Health Services Administration (2020) Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville"},{"issue":"4","key":"16_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1526-4637.2007.00370.x","volume":"9","author":"DA Fishbain","year":"2008","unstructured":"Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS (2008) What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse\/addiction and\/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 9(4):444\u2013459","journal-title":"Pain Med"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/nn1583","volume":"8","author":"MJ Kreek","year":"2005","unstructured":"Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8:1450\u20131457","journal-title":"Nat Neurosci"},{"issue":"4","key":"16_CR13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","volume":"99","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Michaelides M, Baler R (2019) The neuroscience of drug reward and addiction. Physiol Rev 99(4):2115\u20132140","journal-title":"Physiol Rev"},{"issue":"12","key":"16_CR14","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/add.13818","volume":"112","author":"HR Kanzler","year":"2017","unstructured":"Kanzler HR, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E (2017) Precision medicine and pharmacogenetics: what does oncology have that addiction medicine doesn\u2019t? Addiction 112(12):2086\u20132094","journal-title":"Addiction"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00952990902825447","volume":"35","author":"CN Haile","year":"2009","unstructured":"Haile CN, Kosten TR, Kosten TA (2009) Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse 35:161\u2013177","journal-title":"Am J Drug Alcohol Abuse"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.drugalcdep.2017.06.040","volume":"180","author":"EC Prom-Wormley","year":"2017","unstructured":"Prom-Wormley EC, Ebejer J, Dick DM, Bowers MS (2017) The genetic epidemiology of substance use disorder: a review. Drug Alcohol Depend 180:241\u2013259. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.06.040","journal-title":"Drug Alcohol Depend"},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1176\/appi.ajp.161.5.780","volume":"161","author":"AK Malhotra","year":"2004","unstructured":"Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780\u2013796","journal-title":"Am J Psychiatry"},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1176\/appi.ajp.160.10.1830","volume":"160","author":"GM Murphy Jr","year":"2003","unstructured":"Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF (2003) Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:1830\u20131835","journal-title":"Am J Psychiatry"},{"key":"16_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/14622416.7.1.31","volume":"7","author":"S Gupta","year":"2006","unstructured":"Gupta S, Jain S, Brahmachari SK, Kukreti R (2006) Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics 7:31\u201347","journal-title":"Pharmacogenomics"},{"key":"16_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","volume":"47","author":"J deLeon","year":"2006","unstructured":"deLeon J, Armstrong SC, Cozza KL (2006) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics 47:75\u201385","journal-title":"Psychosomatics"},{"issue":"1","key":"16_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","volume":"122","author":"E Spina","year":"2015","unstructured":"Spina E, de Leon J (2015) Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna) 122(1):5\u201328","journal-title":"J Neural Transm (Vienna)"},{"key":"16_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0002-9343(02)01363-3","volume":"113","author":"JF Rogers","year":"2002","unstructured":"Rogers JF, Nafziger AN, Bertino JS Jr (2002) Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113:746\u2013750","journal-title":"Am J Med"},{"issue":"1","key":"16_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/npr2.12003","volume":"38","author":"K Yoshida","year":"2018","unstructured":"Yoshida K, Nishizawa D, Ide S, Ichinohe T, Fukuda KI, Ikeda K (2018) A pharmacogenetics approach to pain management. Neuropsychopharmacol Rep 38(1):2\u20138","journal-title":"Neuropsychopharmacol Rep"},{"issue":"9","key":"16_CR24","volume":"12","author":"JF Ortiz","year":"2020","unstructured":"Ortiz JF, Wirth M, Eskander N, Cozar JC, Fatade O, Rathod B (2020) The genetic foundations of serotonin syndrome, neuroleptic malignant syndrome, and malignant hyperthermia: is there a genetic association between these disorders? Cureus 12(9):e10635","journal-title":"Cureus"},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fpsyt.2019.00432","volume":"10","author":"JP Jarvis","year":"2019","unstructured":"Jarvis JP, Peter AP, Shaman JA (2019) Consequences of CYP2D6 copy-number variation for pharmacogenomics in psychiatry. Front Psych 10:432","journal-title":"Front Psych"},{"issue":"3","key":"16_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/bmb.20952","volume":"44","author":"F Moraes","year":"2016","unstructured":"Moraes F, G\u00f3es A (2016) A decade of human genome project conclusion: scientific diffusion about our genome knowledge. Biochem Mol Biol Educ 44(3):215\u2013223","journal-title":"Biochem Mol Biol Educ"},{"key":"16_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"BE Bernstein","year":"2012","unstructured":"ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57\u201374","journal-title":"Nature"},{"key":"16_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"GR Abecasis","year":"2012","unstructured":"Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491:56\u201365","journal-title":"Nature"},{"key":"16_CR29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature09534","volume":"467","author":"GR Abecasis","year":"2010","unstructured":"Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA (2010) A map of human genome variation from population-scale sequencing. Nature 467:1061\u20131073","journal-title":"Nature"},{"issue":"1","key":"16_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2019.02.003","volume":"177","author":"J Shendure","year":"2019","unstructured":"Shendure J, Findlay GM, Snyder MW (2019) Genomic medicine \u2013 progress, pitfalls, and promise. Cell 177(1):45\u201357","journal-title":"Cell"},{"issue":"1","key":"16_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","volume":"12","author":"CM Lewis","year":"2020","unstructured":"Lewis CM, Vassos E (2020) Polygenic risk scores: from research tools to clinical instruments. Genome Med 12(1):44","journal-title":"Genome Med"},{"key":"16_CR32","doi-asserted-by":"crossref","unstructured":"Wray NR, Lin T, Austin J, McGrath JJ, Hickie IB, Murray GK, Visscher JM (2021) From Basic Science to Clinical Application of Polygenic Risk Scores A Primer. JAMA Psychiatry 78(1):101\u2013109","DOI":"10.1001\/jamapsychiatry.2020.3049"},{"key":"16_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fgene.2020.00578","volume":"11","author":"L Folkersen","year":"2020","unstructured":"Folkersen L, Pain O, Ingason A, Werge T, Lewis CM, Austin J (2020) Impute.me: an open-source, non-profit tool for using data from direct-to-consumer genetic testing to calculate and interpret polygenic risk scores. Front Genet 11:578","journal-title":"Front Genet"},{"issue":"3","key":"16_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/YPG.0000000000000220","volume":"29","author":"VS Palladino","year":"2019","unstructured":"Palladino VS, McNeill R, Reif A, Kittel-Schneider S (2019) Genetic risk factors and gene-environment interactions in adult and childhood attention-deficit\/hyperactivity disorder. Psychiatr Genet 29(3):63\u201378","journal-title":"Psychiatr Genet"},{"issue":"6","key":"16_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1089\/cap.2018.0164","volume":"30","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, Yang B, Qian Y, Cao Q, Chang S, Wang Y, Yang L (2020) The association with quantitative response to attention-deficit\/hyperactivity disorder medication of the previously identified neurodevelopmental network genes. J Child Adolesc Psychopharmacol 30(6):348\u2013354","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpsychires.2019.09.002","volume":"119","author":"J Tomasi","year":"2019","unstructured":"Tomasi J, Lisoway AJ, Zai CC, Harripaul R, M\u00fcller DJ, Zai GCM, McCabe RE, Richter MA, Kennedy JL, Tiwari AK (2019) Towards precision medicine in generalized anxiety disorder: review of genetics and pharmaco(epi)genetics. J Psychiatr Res 119:33\u201347","journal-title":"J Psychiatr Res"},{"issue":"6 Suppl","key":"16_CR37","doi-asserted-by":"publisher","first-page":"S398","DOI":"10.1016\/j.amepre.2007.09.006","volume":"33","author":"CE Lerman","year":"2007","unstructured":"Lerman CE, Schnoll RA, Munaf\u00f2 MR (2007) Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 33(6 Suppl):S398\u2013S405","journal-title":"Am J Prev Med"},{"key":"16_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2014.04.019","volume":"140","author":"SJ Meoller","year":"2014","unstructured":"Meoller SJ, Parvaz MA, Shumay E, Wu S, Beebe-Wang N, Konova AB, Misyrlis M, Alia-Klein N, Goldstein RZ (2014) Monoamine polygenic liability in health and cocaine dependence: imaging genetics study of aversive processing and associations with depression symptomatology. Drug Alcohol Depend 140:17\u201324","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"16_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/10826084.2018.1531430","volume":"54","author":"MC Gerra","year":"2019","unstructured":"Gerra MC, Manfredini M, Cortese E, Antonioni MC, Leonardi C, Magnelli F, Somaini L, Jayanthi S, Cadet JL, Donnini C (2019) Genetic and environmental risk factors for cannabis use: preliminary results for the role of parental care perception. Subst Use Misuse 54(4):670\u2013680","journal-title":"Subst Use Misuse"},{"key":"16_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cobeha.2021.02.013","volume":"39","author":"D Nguyen","year":"2021","unstructured":"Nguyen D, Naffziger EE, Berridge KC (2021) Positive affect: nature and brain bases of liking and wanting. Curr Opin Behav Sci 39:72\u201378","journal-title":"Curr Opin Behav Sci"},{"issue":"2","key":"16_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0006-8993(90)91309-5","volume":"530","author":"JG Pfaus","year":"1990","unstructured":"Pfaus JG, Damsma G, Nomikos GG, Wenkstern DG, Blaha CD, Phillips AG, Fibiger HC (1990) Sexual behavior enhances central dopamine transmission in the male rat. Brain Res 530(2):345\u2013348","journal-title":"Brain Res"},{"issue":"4","key":"16_CR42","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1053-8119(03)00253-2","volume":"19","author":"DM Small","year":"2003","unstructured":"Small DM, Jones-Gotman M, Dagher A (2003) Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. NeuroImage 19(4):1709\u20131715","journal-title":"NeuroImage"},{"issue":"14","key":"16_CR43","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","volume":"85","author":"G Di Chiara","year":"1988","unstructured":"Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85(14):5274\u20135278","journal-title":"Proc Natl Acad Sci USA"},{"key":"16_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2021.615313","volume":"15","author":"JA Mollick","year":"2021","unstructured":"Mollick JA, Chang LJ, Krishnan A, Hazy TE, Krueger KA, Frank GKW, Wager TD, O\u2019Reilly RC (2021) The neural correlates of cued reward omission. Front Hum Neurosci 15:615313","journal-title":"Front Hum Neurosci"},{"issue":"11","key":"16_CR45","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/nn1105-1431","volume":"8","author":"C Dackis","year":"2005","unstructured":"Dackis C, O\u2018Brien C (2005) Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci 8(11):1431\u20131436","journal-title":"Nat Neurosci"},{"issue":"1","key":"16_CR46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41467-020-20526-0","volume":"12","author":"AF Garcia","year":"2021","unstructured":"Garcia AF, Crummy EA, Webb IG, Nooney MN, Ferguson SM (2021) Distinct populations of cortical pyramidal neurons mediate drug reward and aversion. Nat Commun 12(1):182","journal-title":"Nat Commun"},{"key":"16_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fnins.2020.00569","volume":"14","author":"EA Crummy","year":"2020","unstructured":"Crummy EA, O\u2019Neal TJ, Baskin BM, Ferguson SM (2020) One is not enough: understanding and modeling polysubstance use. Front Neurosci 14:569","journal-title":"Front Neurosci"},{"issue":"1","key":"16_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2210-6-6","volume":"6","author":"D Han","year":"2006","unstructured":"Han D, Gu H (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6(1):6","journal-title":"BMC Pharmacol"},{"key":"16_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neubiorev.2020.11.004","volume":"120","author":"HE Webber","year":"2021","unstructured":"Webber HE, Lopez-Gamundi P, Stamatovich SN, de Wit H, Wardle MC (2021) Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults. Neurosci Biobehav Rev 120:123\u2013158","journal-title":"Neurosci Biobehav Rev"},{"key":"16_CR50","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrn3110","volume":"12","author":"M Heilig","year":"2011","unstructured":"Heilig M, Goldman D, Berrettini W, O'Brien CP (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12:670\u2013684","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"16_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3969\/j.issn.1002-0829.2014.02.002","volume":"26","author":"H Ma","year":"2014","unstructured":"Ma H, Zhu G (2014) The dopamine system and alcohol dependence. Shanghai Arch Psychiatry 26(2):61\u201368. https:\/\/doi.org\/10.3969\/j.issn.1002-0829.2014.02.002","journal-title":"Shanghai Arch Psychiatry"},{"key":"16_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0165-6147(92)90060-J","volume":"13","author":"GF Koob","year":"1992","unstructured":"Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177\u2013184","journal-title":"Trends Pharmacol Sci"},{"key":"16_CR53","first-page":"250","volume":"267","author":"F Weiss","year":"1993","unstructured":"Weiss F, Lorang MT, Bloom FE, Koob GF (1993) Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 267:250\u2013258","journal-title":"J Pharmacol Exp Ther"},{"key":"16_CR54","first-page":"219","volume":"239","author":"A Imperato","year":"1986","unstructured":"Imperato A, Di Chiara G (1986) Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 239:219\u2013228","journal-title":"J Pharmacol Exp Ther"},{"key":"16_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107573","volume":"212","author":"AA Vena","year":"2020","unstructured":"Vena AA, Zandy SL, Cofres\u00ed RU, Gonzales RA (2020) Behavioral, neurobiological, and neurochemical mechanisms of ethanol self-administration: a translational review. Pharmacol Ther 212:107573","journal-title":"Pharmacol Ther"},{"key":"16_CR56","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.tins.2012.06.007","volume":"35","author":"R Bourdy","year":"2012","unstructured":"Bourdy R, Barrot M (2012) A new control center for dopaminergic systems: pulling the VTA by the tail. Trends Neurosci 35:681\u2013690","journal-title":"Trends Neurosci"},{"key":"16_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","volume":"12","author":"SW Johnson","year":"1992","unstructured":"Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483\u2013488","journal-title":"J Neurosci"},{"key":"16_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0165-0173(98)00019-8","volume":"28","author":"KC Berridge","year":"1998","unstructured":"Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309\u2013369","journal-title":"Brain Res Brain Res Rev"},{"issue":"13","key":"16_CR59","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1001\/jama.1991.03470130073032","volume":"266","author":"DE Comings","year":"1991","unstructured":"Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D, Knell E, Kocsis P, Baumgarten R, Kovacs BW et al (1991) The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 266(13):1793\u20131800","journal-title":"JAMA"},{"key":"16_CR60","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1023\/A:1022191012698","volume":"33","author":"VE Golimbet","year":"2003","unstructured":"Golimbet VE, Aksenova MG, Nosikov VV, Orlova VA, Kaleda VG (2003) Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol 33:223\u2013225","journal-title":"Neurosci Behav Physiol"},{"key":"16_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00008571-199606000-00004","volume":"6","author":"DE Comings","year":"1996","unstructured":"Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, Dietz G, Gade R (1996) A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 6:223\u2013234","journal-title":"Pharmacogenetics"},{"key":"16_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0741-8329(91)90693-Q","volume":"8","author":"K Blum","year":"1991","unstructured":"Blum K, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T, Ozkaragoz T, Fitch RJ, Sadlack F, Sheffield D et al (1991) Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 8:409\u2013416","journal-title":"Alcohol"},{"key":"16_CR63","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/0006-3223(95)00483-1","volume":"40","author":"AM Persico","year":"1996","unstructured":"Persico AM, Bird G, Gabbay FH, Uhl GR (1996) D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 40:776\u2013784","journal-title":"Biol Psychiatry"},{"key":"16_CR64","first-page":"35","volume":"2","author":"EP Noble","year":"1994","unstructured":"Noble EP (1994) Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Alcohol Alcohol Suppl 2:35\u201343","journal-title":"Alcohol Alcohol Suppl"},{"key":"16_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/14622200410001734030","volume":"6","author":"M Munafo","year":"2004","unstructured":"Munafo M, Clark T, Johnstone E, Murphy M, Walton R (2004) The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6:583\u2013597","journal-title":"Nicotine Tob Res"},{"issue":"5","key":"16_CR66","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/1096-8628(20001009)96:5<592::AID-AJMG3>3.0.CO;2-Y","volume":"96","author":"BR Lawford","year":"2000","unstructured":"Lawford BR, Young RM, Noble EP, Sargent J, Rowell J, Shadforth S, Zhang X, Ritchie T (2000) The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96(5):592\u2013598","journal-title":"Am J Med Genet"},{"key":"16_CR67","doi-asserted-by":"publisher","first-page":"20552","DOI":"10.1073\/pnas.0707106104","volume":"104","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee ML, Xiao T, Papp A, Wang D, Sadee W (2007) Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A 104:20552\u201320557. do","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR68","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/npp.2010.208","volume":"36","author":"RA Moyer","year":"2011","unstructured":"Moyer RA, Wang D, Papp AC, Smith RM, Duque L, Mash DC, Sadee W (2011) Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology 36:753\u2013762","journal-title":"Neuropsychopharmacology"},{"key":"16_CR69","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.pnpbp.2009.02.021","volume":"33","author":"MM Hirvonen","year":"2009","unstructured":"Hirvonen MM, Lumme V, Hirvonen J, Pesonen U, Nagren K, Vahlberg T, Scheinin H, Hietala J (2009) C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog Neuro-Psychopharmacol Biol Psychiatry 33:630\u2013636","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"3","key":"16_CR70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/hmg\/ddg055","volume":"12","author":"J Duan","year":"2003","unstructured":"Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205\u2013216","journal-title":"Hum Mol Genet"},{"issue":"2","key":"16_CR71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/14622416.10.2.277","volume":"10","author":"M Gupta","year":"2009","unstructured":"Gupta M, Chauhan C, Bhatnagar P, Gupta S, Grover S, Singh PK, Purushottam M, Mukherjee O, Jain S, Brahmachari SK, Kukreti R (2009) Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 10(2):277\u2013291","journal-title":"Pharmacogenomics"},{"key":"16_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1369-1600.2012.00490.x","volume":"18","author":"JL Meyers","year":"2013","unstructured":"Meyers JL, Nyman E, Loukola A, Rose RJ, Kaprio J, Dick DM (2013) The association between DRD2\/ANKK1 and genetically informed measures of alcohol use and problems. Addict Biol 18:523\u2013536","journal-title":"Addict Biol"},{"key":"16_CR73","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2147\/NDT.S118614","volume":"12","author":"H He","year":"2016","unstructured":"He H, Wu H, Yang L, Gao F, Fan Y, Feng J, Ma X (2016) Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis. Neuropsychiatr Dis Treat 12:3129\u20133144","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"16_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12993-016-0114-z","volume":"12","author":"TB Gonzalez-Castro","year":"2016","unstructured":"Gonzalez-Castro TB, Hernendez-Diaz Y, Juarez-Rojop IE, Lopez-Narvaez ML, Tovilla-Zarate CA, Genis-Mendoza A, Alpuin-Reyes M (2016) The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis. Behav Brain Funct 12(1):29","journal-title":"Behav Brain Funct"},{"issue":"4","key":"16_CR75","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00429-021-02227-6","volume":"226","author":"EK Diekhof","year":"2021","unstructured":"Diekhof EK, Richter A, Brodmann K, Gruber O (2021) Dopamine multilocus genetic profiles predict sex differences in reactivity of the human reward system. Brain Struct Funct 226(4):1099\u20131114","journal-title":"Brain Struct Funct"},{"issue":"2","key":"16_CR76","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbrc.2004.04.194","volume":"319","author":"J Zha","year":"2004","unstructured":"Zha J, Zhou Q, Xu LG, Chen D, Li L, Zhai Z, Shu HB (2004) RIP5 is a RIP-homologous inducer of cell death. Biochem Biophys Res Commun 319(2):298\u2013303","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"16_CR77","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.1990.03440150063027","volume":"263","author":"K Blum","year":"1990","unstructured":"Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB (1990) Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 263(15):2055\u20132060","journal-title":"JAMA"},{"issue":"3","key":"16_CR78","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.mp.4000532","volume":"4","author":"EG J\u00f6nsson","year":"1999","unstructured":"J\u00f6nsson EG, N\u00f6then MM, Gr\u00fcnhage F, Farde L, Nakashima Y, Propping P, Sedvall GC (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4(3):290\u2013296","journal-title":"Mol Psychiatry"},{"issue":"1\u20132","key":"16_CR79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0006-8993(96)00068-6","volume":"718","author":"T Ritchie","year":"1996","unstructured":"Ritchie T, Noble EP (1996) [3H]naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism. Brain Res 718(1\u20132):193\u2013197","journal-title":"Brain Res"},{"issue":"6","key":"16_CR80","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1176\/ajp.147.6.719","volume":"147","author":"ND Volkow","year":"1990","unstructured":"Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D et al (1990) Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147(6):719\u2013724","journal-title":"Am J Psychiatry"},{"key":"16_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107583","volume":"213","author":"R Chen","year":"2020","unstructured":"Chen R, Ferris MJ, Wang S (2020) Dopamine D2 autoreceptor interactome: targeting the receptor complex as strategy for treatment of substance use disorder. Pharmacol Ther 213:107583","journal-title":"Pharmacol Ther"},{"issue":"9","key":"16_CR82","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/j.1530-0277.1996.tb05936.x","volume":"20","author":"ND Volkow","year":"1996","unstructured":"Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Piscani K (1996) Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20(9):1594\u20131598","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"16_CR83","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0893-133X(96)00184-4","volume":"16","author":"GJ Wang","year":"1997","unstructured":"Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, Pascani K (1997) Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16(2):174\u2013182","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"16_CR84","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3390\/ijms21072516","volume":"21","author":"A Koeneke","year":"2020","unstructured":"Koeneke A, Ponce G, Troya-Valesca J, Palomo T, Hoenicka J (2020) Ankyrin repeat and kinase domain containing 1 gene, and addiction vulnerability. Int J Mol Sci 21(7):2516","journal-title":"Int J Mol Sci"},{"issue":"11","key":"16_CR85","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14940","volume":"2","author":"Y Jung","year":"2019","unstructured":"Jung Y, Montel RA, Shen PH, Mash DC, Goldman D (2019) Assessment of the association of D2 dopamine receptor gene and reported allele frequencies with alcohol use disorders: a systematic review and meta-analysis. JAMA Netw Open 2(11):e1914940","journal-title":"JAMA Netw Open"},{"issue":"15","key":"16_CR86","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3390\/ijerph16152687","volume":"16","author":"A Grzywacz","year":"2019","unstructured":"Grzywacz A, Chmielowiec J, Chmielowiec K, Mroczek B, Masiak J, Suchanecka A, Sipak-Szmigiel O, Szumilas K, Trybek G (2019) The ankyrin repeat and kinase domain containing 1 gene polymorphism (ANKK1 Taq1A) and personality traits in addicted subjects. Int J Environ Res Public Health 16(15):2687","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"16_CR87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12640-010-9219-6","volume":"20","author":"E Garrido","year":"2011","unstructured":"Garrido E, Palomo T, Ponce G, Garcia-Consuegra I, Jimenez-Arriero MA, Hoenicka J (2011) The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine. Neurotox Res 20(1):32\u201339","journal-title":"Neurotox Res"},{"issue":"3","key":"16_CR88","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.biopsych.2012.07.011","volume":"73","author":"TR Kosten","year":"2013","unstructured":"Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA (2013) Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 73(3):219\u2013224","journal-title":"Biol Psychiatry"},{"issue":"7","key":"16_CR89","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/FPC.0b013e328361c39d","volume":"23","author":"CJ Spellicy","year":"2013","unstructured":"Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA (2013) ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics 23(7):333\u2013340","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"16_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/ajad.12891","volume":"28","author":"JP Kampangkaew","year":"2019","unstructured":"Kampangkaew JP, Spellicy CJ, Nielsen EM, Harding MJ, Ye A, Hamon SC, Kosten TR, Nielsen DA (2019) Pharmacogenetic roles of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. Am J Addict 28(4):311\u2013317","journal-title":"Am J Addict"},{"issue":"3","key":"16_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/YPG.0000000000000279","volume":"31","author":"PS Thomas Jr","year":"2021","unstructured":"Thomas PS Jr, Nielsen EM, Spellicy CJ, Harding MJ, Ye A, Patriquin M, Hamon SC, Kosten TR, Nielsen DA (2021) The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatr Genet 31(3):88\u201394","journal-title":"Psychiatr Genet"},{"issue":"3","key":"16_CR92","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/adb.12611","volume":"24","author":"X Zhang","year":"2019","unstructured":"Zhang X, Nielsen DA, Domingo CB, Shorter DI, Nielsen EM, Kosten TR (2019) Pharmacogenetics of dopamine beta-hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol 24(3):531\u2013538","journal-title":"Addict Biol"},{"issue":"1","key":"16_CR93","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1530-0277.1992.tb00639.x","volume":"16","author":"JI Balldin","year":"1992","unstructured":"Balldin JI, Berggren UC, Lindstedt G (1992) Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcohol Clin Exp Res 16(1):71\u201374","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"16_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/YPG.0000000000000095","volume":"25","author":"MA Patriquin","year":"2015","unstructured":"Patriquin MA, Bauer IE, Soares JC, Graham DP, Nielsen DA (2015) Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet 25(5):181\u2013193","journal-title":"Psychiatr Genet"},{"issue":"2","key":"16_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0376-8716(93)80008-3","volume":"32","author":"J Balldin","year":"1993","unstructured":"Balldin J, Berggren U, Lindstedt G, Sundkler A (1993) Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism. Drug Alcohol Depend 32(2):159\u2013162","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"16_CR96","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nm0495-337","volume":"1","author":"BR Lawford","year":"1995","unstructured":"Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, Ritchie T, Noble EP (1995) Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1(4):337\u2013341","journal-title":"Nat Med"},{"key":"16_CR97","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/00008571-200111000-00002","volume":"11","author":"MJ Lucht","year":"2001","unstructured":"Lucht MJ, Kuehn KU, Schroeder W, Armbruster J, Abraham G, Schattenberg A, Gaensicke M, Barnow S, Tretzel H, Herrmann FH, Freyberger HJ (2001) Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal. Pharmacogenetics 11:647\u2013653","journal-title":"Pharmacogenetics"},{"key":"16_CR98","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1369-1600.2009.00159.x","volume":"14","author":"W Ooteman","year":"2009","unstructured":"Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W (2009) Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 14:328\u2013337","journal-title":"Addict Biol"},{"key":"16_CR99","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/TACG.S206745","volume":"12","author":"MS Zastrozhin","year":"2019","unstructured":"Zastrozhin MS, Skryabin VY, Mrioshkin SS, Bryun EA, Sychev DA (2019) Pharmacogenetics of alcohol addiction: current perspectives. Appl Clin Genet 12:131\u2013140","journal-title":"Appl Clin Genet"},{"key":"16_CR100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-2999(88)90399-8","volume":"155","author":"DW Choi","year":"1988","unstructured":"Choi DW, Viseskul V (1988) Opioids and non-opioid enantiomers selectively attenuate N-methyl-D-aspartate neurotoxicity on cortical neurons. Eur J Pharmacol 155:27\u201335","journal-title":"Eur J Pharmacol"},{"key":"16_CR101","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","volume":"193","author":"VP Dole","year":"1965","unstructured":"Dole VP, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193:646\u2013650","journal-title":"JAMA"},{"key":"16_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.57.1.1","volume":"57","author":"MJ Kreek","year":"2005","unstructured":"Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA (2005) Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57:1\u201326","journal-title":"Pharmacol Rev"},{"key":"16_CR103","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/FPC.0b013e328320a3fd","volume":"19","author":"A Doehring","year":"2009","unstructured":"Doehring A, Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G, Harder S, Lotsch J (2009) Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 19:407\u2013414","journal-title":"Pharmacogenet Genomics"},{"key":"16_CR104","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","volume":"32","author":"S Crettol","year":"2008","unstructured":"Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Deglon JJ, Preisig M, Eap CB (2008) Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 32:1722\u20131727","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"16_CR105","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fpsyt.2019.00626","volume":"10","author":"JA Burns","year":"2019","unstructured":"Burns JA, Kroll DS, Feldman DE, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ (2019) Molecular imaging of opioid and dopamine systems: insights into the pharmacogenetics of opioid use disorders. Front Psych 10:626","journal-title":"Front Psych"},{"issue":"11","key":"16_CR106","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2217\/pgs.11.96","volume":"12","author":"CC Hung","year":"2011","unstructured":"Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, Lane HY (2011) Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12(11):1525\u20131533","journal-title":"Pharmacogenomics"},{"issue":"Suppl 2","key":"16_CR107","doi-asserted-by":"publisher","first-page":"S787","DOI":"10.4103\/jpbs.JPBS_248_19","volume":"12","author":"Z Zahari","year":"2020","unstructured":"Zahari Z, Lee CS, Ibrahim MA, Musa N, Yasin MAM, Lee YY, Tan SC, Mohamad N, Ismail R (2020) Influence of DRD2 polymorphisms on the clinical outcomes of opioid-dependent patients on methadone maintenance therapy. J Pharm Bioallied Sci 12(Suppl 2):S787\u2013S803. https:\/\/doi.org\/10.4103\/jpbs.JPBS_248_19","journal-title":"J Pharm Bioallied Sci"},{"key":"16_CR108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/358149a0","volume":"358","author":"HH Van Tol","year":"1992","unstructured":"Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358:149\u2013152","journal-title":"Nature"},{"issue":"1","key":"16_CR109","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12889-021-10160-w","volume":"21","author":"C Paquet","year":"2021","unstructured":"Paquet C, Portella AK, Moore S, Ma Y, Dagher A, Meaney MJ, Kennedy JL, Levitan RD, Silveira PP, Dube L (2021) Dopamine D4 receptor gene polymorphism (DRD4 VNTR) moderates real-world behavioural response to the food retail environment in children. BMC Public Health 21(1):145","journal-title":"BMC Public Health"},{"key":"16_CR110","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1046\/j.1471-4159.1995.65031157.x","volume":"65","author":"V Asghari","year":"1995","unstructured":"Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH (1995) Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65:1157\u20131165","journal-title":"J Neurochem"},{"key":"16_CR111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1037\/0278-6133.21.2.139","volume":"21","author":"KE Hutchison","year":"2002","unstructured":"Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM (2002) The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 21:139\u2013146","journal-title":"Health Psychol"},{"issue":"3","key":"16_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12770","volume":"25","author":"AM Daurio","year":"2020","unstructured":"Daurio AM, Dechaine SL, Modabbernia A, Leggio L (2020) Parsing out the role of dopamine D4 receptor gene (DRD4) on alcohol-related phenotypes: a meta-analysis and systematic review. Addict Biol 25(3):e12770","journal-title":"Addict Biol"},{"issue":"4","key":"16_CR113","first-page":"248","volume":"56","author":"Uysal MA, Sever \u00dc, Nursal AF, Yedikule Smoking Cessation Study Group, Pehllvan S","year":"2019","unstructured":"Uysal MA, Sever \u00dc, Nursal AF, Yedikule Smoking Cessation Study Group, Pehllvan S (2019) Dopamine D4 receptor gene exon III VNTR variant influences smoking status in Turkish population. Noro Psikiyatr Ars 56(4):248\u2013252","journal-title":"Noro Psikiyatr Ars"},{"issue":"8","key":"16_CR114","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/nu12082288","volume":"12","author":"L Botticelli","year":"2020","unstructured":"Botticelli L, Di Bonaventura EM, Del Bello F, Giorgioni G, Piergentili A, Romano A, Quaglia W, Cifani C, Di Bonaventura MVM (2020) Underlying susceptibility to eating disorders and drug abuse: genetic and pharmacological aspects of dopamine D4 receptors. Nutrients 12(8):2288","journal-title":"Nutrients"},{"key":"16_CR115","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/sj.npp.1300264","volume":"28","author":"KE Hutchison","year":"2003","unstructured":"Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28:1882\u20131888","journal-title":"Neuropsychopharmacology"},{"key":"16_CR116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s002130000629","volume":"155","author":"KE Hutchison","year":"2001","unstructured":"Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A (2001) Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 155:27\u201334","journal-title":"Psychopharmacology"},{"key":"16_CR117","first-page":"71","volume":"17","author":"S Kaufman","year":"1965","unstructured":"Kaufman S, Friedman S (1965) Dopamine-Beta-Hydroxylase. Pharmacol Rev 17:71\u2013100","journal-title":"Pharmacol Rev"},{"key":"16_CR118","first-page":"133","volume":"30","author":"RM Weinshilboum","year":"1978","unstructured":"Weinshilboum RM (1978) Serum dopamine beta-hydroxylase. Pharmacol Rev 30:133\u2013166","journal-title":"Pharmacol Rev"},{"key":"16_CR119","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0079-6123(00)26014-7","volume":"126","author":"AF Arnsten","year":"2000","unstructured":"Arnsten AF (2000) Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog Brain Res 126:183\u2013192","journal-title":"Prog Brain Res"},{"issue":"3","key":"16_CR120","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/cercor\/bhaa333","volume":"31","author":"J Wang","year":"2021","unstructured":"Wang J, John Y, Barbas H (2021) Pathways for contextual memory: the primate hippocampal pathway to anterior cingulate cortex. Cereb Cortex 31(3):1807\u20131826","journal-title":"Cereb Cortex"},{"key":"16_CR121","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1155\/NP.2000.133","volume":"7","author":"AF Arnsten","year":"2000","unstructured":"Arnsten AF (2000) Through the looking glass: differential noradrenergic modulation of prefrontal cortical function. Neural Plast 7:133\u2013146","journal-title":"Neural Plast"},{"issue":"10","key":"16_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000793","volume":"18","author":"N Borderies","year":"2020","unstructured":"Borderies N, Bornert P, Gilardeau S, Bouret S (2020) Pharmacological evidence for the implication of noradrenaline in effort. PLoS Biol 18(10):e3000793","journal-title":"PLoS Biol"},{"issue":"9","key":"16_CR123","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/scan\/nst122","volume":"9","author":"P Gong","year":"2014","unstructured":"Gong P, Liu J, Li S, Zhou X (2014) Dopamine beta-hydroxylase gene modulates individuals\u2019 empathic ability. Soc Cogn Affect Neurosci 9(9):1341\u20131345","journal-title":"Soc Cogn Affect Neurosci"},{"key":"16_CR124","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev.bi.57.070188.003003","volume":"57","author":"LC Stewart","year":"1988","unstructured":"Stewart LC, Klinman JP (1988) Dopamine beta-hydroxylase of adrenal chromaffin granules: structure and function. Annu Rev Biochem 57:551\u2013592","journal-title":"Annu Rev Biochem"},{"key":"16_CR125","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1126\/science.181.4103.943","volume":"181","author":"RM Weinshilboum","year":"1973","unstructured":"Weinshilboum RM, Raymond FA, Elveback LR, Weidman WH (1973) Serum dopamine-beta-hydroxylase activity: sibling-sibling correlation. Science 181:943\u2013945","journal-title":"Science"},{"key":"16_CR126","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0022-3956(86)90020-8","volume":"20","author":"G Oxenstierna","year":"1986","unstructured":"Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G (1986) Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals--a genetic study. J Psychiatr Res 20:19\u201329","journal-title":"J Psychiatr Res"},{"issue":"1","key":"16_CR127","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s004390050310","volume":"99","author":"J Wei","year":"1997","unstructured":"Wei J, Ramchand CN, Hemmings GP (1997) Possible control of dopamine beta-hydroxylase via a codominant mechanism associated with the polymorphic (GT)n repeat at its gene locus in healthy individuals. Hum Genet 99(1):52\u201355","journal-title":"Hum Genet"},{"issue":"7","key":"16_CR128","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S0006-3223(96)00218-1","volume":"41","author":"J Wei","year":"1997","unstructured":"Wei J, Xu HM, Ramchand CN, Hemmings GP (1997) Is the polymorphic microsatellite repeat of the dopamine beta-hydroxylase gene associated with biochemical variability of the catecholamine pathway in schizophrenia? Biol Psychiatry 41(7):762\u2013767","journal-title":"Biol Psychiatry"},{"issue":"5","key":"16_CR129","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s004390050736","volume":"102","author":"JF Cubells","year":"1998","unstructured":"Cubells JF, van Kammen DP, Kelley ME, Anderson GM, O'Connor DT, Price LH, Malison R, Rao PA, Kobayashi K, Nagatsu T, Gelernter J (1998) Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet 102(5):533\u2013540","journal-title":"Hum Genet"},{"issue":"1","key":"16_CR130","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/sj.mp.4000657","volume":"5","author":"JF Cubells","year":"2000","unstructured":"Cubells JF, Kranzler HR, McCance-Katz E, Anderson GM, Malison RT, Price LH, Gelernter J (2000) A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 5(1):56\u201363","journal-title":"Mol Psychiatry"},{"issue":"6","key":"16_CR131","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1086\/375499","volume":"72","author":"CP Zabetian","year":"2003","unstructured":"Zabetian CP, Buxbaum SG, Elston RC, Kohnke MD, Anderson GM, Gelernter J, Cubells JF (2003) The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Hum Genet 72(6):1389\u20131400","journal-title":"Am J Hum Genet"},{"issue":"2","key":"16_CR132","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1086\/318198","volume":"68","author":"CP Zabetian","year":"2001","unstructured":"Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF (2001) A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68(2):515\u2013522","journal-title":"Am J Hum Genet"},{"issue":"3","key":"16_CR133","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10571-007-9256-8","volume":"28","author":"N Bhaduri","year":"2008","unstructured":"Bhaduri N, Mukhopadhyay K (2008) Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: A study on Eastern Indian population. Cell Mol Neurobiol 28(3):343\u2013350","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"16_CR134","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.drugalcdep.2013.07.002","volume":"133","author":"UW Preuss","year":"2013","unstructured":"Preuss UW, Wurst FM, Ridinger M, Rujescu D, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P (2013) Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: results from a large multicenter association study. Drug Alcohol Depend 133(2):459\u2013467","journal-title":"Drug Alcohol Depend"},{"key":"16_CR135","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.neulet.2013.02.049","volume":"541","author":"X Xie","year":"2013","unstructured":"Xie X, Xu L, Liu H, Chen W, Zhuang D, Zhang J, Duan S, Zhou W (2013) Positive association between--1021TT genotype of dopamine beta hydroxylase gene and progressive behavior of injection heroin users. Neurosci Lett 541:258\u2013262","journal-title":"Neurosci Lett"},{"issue":"1","key":"16_CR136","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12881-020-01092-0","volume":"21","author":"Y Li","year":"2020","unstructured":"Li Y, Zhu Y, Lai J, Shi X, Chen Y, Zhang J, Wei S (2020) Association studies of dopamine synthesis and metabolism genes with multiple phenotypes of heroin dependence. BMC Med Genet 21(1):157","journal-title":"BMC Med Genet"},{"issue":"1","key":"16_CR137","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JAD-190991","volume":"73","author":"MB Leko","year":"2020","unstructured":"Leko MB, Perkovi\u0107 MN, Klepac N, \u0160trac D\u0160, Borove\u010dki F, Pivac N, Hof PR, \u0160imi\u0107 G (2020) Relationships of cerebrospinal fluid Alzheimer\u2019s disease biomarkers and COMT, DBH, and MAOB single nucleotide polymorphisms. J Alzheimers Dis 73(1):135\u2013145","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"16_CR138","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10072-018-3543-7","volume":"39","author":"S Kang","year":"2018","unstructured":"Kang S, Bi M, Du S, Jiao Q, Jiang H (2018) Association of the rs1611115 polymorphism in DBH gene with Parkinson\u2019s disease: a meta-analysis. Neurol Sci 39(12):2085\u20132089","journal-title":"Neurol Sci"},{"key":"16_CR139","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","volume":"58","author":"BA Martell","year":"2005","unstructured":"Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58:158\u2013164","journal-title":"Biol Psychiatry"},{"key":"16_CR140","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neulet.2013.02.037","volume":"541","author":"TR Kosten","year":"2013","unstructured":"Kosten TR, Domingo CB, Hamon SC, Nielsen DA (2013) DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett 541:29\u201333","journal-title":"Neurosci Lett"},{"key":"16_CR141","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","volume":"89","author":"R Spanagel","year":"1992","unstructured":"Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89:2046\u20132050","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR142","first-page":"1067","volume":"244","author":"G Di Chiara","year":"1988","unstructured":"Di Chiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067\u20131080","journal-title":"J Pharmacol Exp Ther"},{"key":"16_CR143","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/j.1471-4159.1990.tb04963.x","volume":"55","author":"R Spanagel","year":"1990","unstructured":"Spanagel R, Herz A, Shippenberg TS (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55:1734\u20131740","journal-title":"J Neurochem"},{"key":"16_CR144","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.mp.4001504","volume":"9","author":"G Bart","year":"2004","unstructured":"Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, Ott J, Kreek MJ (2004) Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in Central Sweden. Mol Psychiatry 9:547\u2013549","journal-title":"Mol Psychiatry"},{"key":"16_CR145","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1471-4159.2009.06472.x","volume":"112","author":"I Deb","year":"2010","unstructured":"Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S (2010) Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem 112:486\u2013496","journal-title":"J Neurochem"},{"key":"16_CR146","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/sj.mp.4000331","volume":"2","author":"AW Bergen","year":"1997","unstructured":"Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D (1997) Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2:490\u2013494","journal-title":"Mol Psychiatry"},{"key":"16_CR147","doi-asserted-by":"publisher","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","volume":"95","author":"C Bond","year":"1998","unstructured":"Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608\u20139613","journal-title":"Proc Natl Acad Sci USA"},{"key":"16_CR148","doi-asserted-by":"publisher","first-page":"32618","DOI":"10.1074\/jbc.M504942200","volume":"280","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:32618\u201332624","journal-title":"J Biol Chem"},{"key":"16_CR149","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","volume":"103","author":"T Kroslak","year":"2007","unstructured":"Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ (2007) The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103:77\u201387","journal-title":"J Neurochem"},{"key":"16_CR150","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0893-133X(01)00294-9","volume":"26","author":"GS Wand","year":"2002","unstructured":"Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26:106\u2013114","journal-title":"Neuropsychopharmacology"},{"key":"16_CR151","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ajmg.b.10054","volume":"118B","author":"CA Hernandez-Avila","year":"2003","unstructured":"Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 118B:60\u201365","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"7","key":"16_CR152","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41380-019-0507-0","volume":"25","author":"A Halikere","year":"2020","unstructured":"Halikere A, Popova D, Scarnati MS, Hamod A, Swerdel MR, Moore JC, Tischfield JA, Hart RP, Pang ZP (2020) Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. Mol Psychiatry 25(7):1406\u20131419","journal-title":"Mol Psychiatry"},{"issue":"2","key":"16_CR153","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biopsych.2007.05.001","volume":"63","author":"J Kakko","year":"2008","unstructured":"Kakko J, von Wachenfeldt J, Svanborg JD, Lidstrom J, Barr CS, Heilig M (2008) Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry 63(2):172\u2013177","journal-title":"Biol Psychiatry"},{"key":"16_CR154","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300598","volume":"30","author":"G Bart","year":"2005","unstructured":"Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M (2005) Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in Central Sweden. Neuropsychopharmacology 30:417\u2013422","journal-title":"Neuropsychopharmacology"},{"key":"16_CR155","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/alcalc\/agt050","volume":"48","author":"N Rouvinen-Lagerstrom","year":"2013","unstructured":"Rouvinen-Lagerstrom N, Lahti J, Alho H, Kovanen L, Aalto M, Partonen T, Silander K, Sinclair D, Raikkonen K, Eriksson JG, Palotie A, Koskinen S, Saarikoski ST (2013) Mu-opioid receptor gene (OPRM1) polymorphism A118G: lack of association in finnish populations with alcohol dependence or alcohol consumption. Alcohol Alcohol 48:519\u2013525","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"16_CR156","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.npep.2013.08.002","volume":"47","author":"B Cupic","year":"2013","unstructured":"Cupic B, Stefulj J, Zapletal E, Matosic A, Bordukalo-Niksic T, Cicin-Sain L, Gabrilovac J (2013) Opioid system genes in alcoholism: A case-control study in Croatian population. Neuropeptides 47(5):315\u2013319","journal-title":"Neuropeptides"},{"key":"16_CR157","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1097\/01.ALC.0000148114.34000.B9","volume":"28","author":"LA Ray","year":"2004","unstructured":"Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28:1789\u20131795","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR158","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/00001756-200303240-00008","volume":"14","author":"EC Tan","year":"2003","unstructured":"Tan EC, Tan CH, Karupathivan U, Yap EP (2003) Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 14:569\u2013572","journal-title":"Neuroreport"},{"issue":"10","key":"16_CR159","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1001\/jamapsychiatry.2020.1206","volume":"77","author":"H Zhou","year":"2020","unstructured":"Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, Tate JP, Dao C, Xu K, Polimanti R, Farrer LA, Justice AC, Kranzler HR, Gelernter J, Veterans Affairs Million Veteran Program (2020) Association of OPRM1 functional coding variant with opioid use disorder: a genome-wide association study. JAMA Psychiat 77(10):1072\u20131080","journal-title":"JAMA Psychiat"},{"key":"16_CR160","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.neulet.2013.02.018","volume":"542","author":"TK Clarke","year":"2013","unstructured":"Clarke TK, Crist RC, Kampman KM, Dackis CA, Pettinati HM, O\u2019Brien CP, Oslin DW, Ferraro TN, Lohoff FW, Berrettini WH (2013) Low frequency genetic variants in the \u03bc-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. Neurosci Lett 542:71\u201375","journal-title":"Neurosci Lett"},{"issue":"7","key":"16_CR161","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1530-0277.2008.00735.x","volume":"32","author":"AJ Arias","year":"2008","unstructured":"Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Makela R, Kranzler HR (2008) Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 32(7):1159\u20131166","journal-title":"Alcohol Clin Exp Res"},{"issue":"17","key":"16_CR162","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2013.3411","volume":"309","author":"EM Wachman","year":"2013","unstructured":"Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM (2013) Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 309(17):1821\u20131827","journal-title":"JAMA"},{"key":"16_CR163","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.drugalcdep.2015.07.001","volume":"155","author":"EM Wachman","year":"2015","unstructured":"Wachman EM, Hayes MJ, Sherva R, Brown MS, Davis JM, Farrer LA, Nielsen DA (2015) Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend 155:253\u2013259","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"16_CR164","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2217\/pgs.13.58","volume":"14","author":"O Levran","year":"2013","unstructured":"Levran O, Peles E, Randesi M, Shu X, Ott J, Shen PH, Adelson M, Kreek MJ (2013) Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics 14(7):755\u2013768","journal-title":"Pharmacogenomics"},{"issue":"10","key":"16_CR165","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.euroneuro.2012.02.002","volume":"22","author":"SC Wang","year":"2012","unstructured":"Wang SC, Tsou HH, Chen CH, Chen YT, Ho IK, Hsiao CF, Chou SY, Lin YF, Fang KC, Huang CL, Su LW, Fang YC, Liu ML, Wu HY, Lin KM, Liu SC, Kuo HW, Chiang IC, Chen AC, Tian JN, Liu YL (2012) Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur Neuropsychopharmacol 22(10):695\u2013703","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"16_CR166","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/tpj.2016.89","volume":"18","author":"RC Crist","year":"2018","unstructured":"Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, Saxon AJ, Ling W, Berrettini WH (2018) A polymorphism in the OPRM1 3\u2032-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18(1):173\u2013179","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"16_CR167","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159043359477","volume":"2","author":"K Lutfy","year":"2004","unstructured":"Lutfy K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2(4):395\u2013402","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"16_CR168","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13735","volume":"1425","author":"J Muriel","year":"2018","unstructured":"Muriel J, Margarit C, Planelles B, Serralta MJ, Puga C, Inda MD, Cutillas E, Morales D, Horga JF, Peiro AM (2018) OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients. Ann N Y Acad Sci 1425(1):82\u201393","journal-title":"Ann N Y Acad Sci"},{"key":"16_CR169","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.npp.1301513","volume":"33","author":"FM Filbey","year":"2008","unstructured":"Filbey FM, Claus E, Audette AR, Niculescu M, Banich MT, Tanabe J, Du YP, Hutchison KE (2008) Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. Neuropsychopharmacology 33:1391\u20131401","journal-title":"Neuropsychopharmacology"},{"key":"16_CR170","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/mp.2010.56","volume":"16","author":"VA Ramchandani","year":"2011","unstructured":"Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16:809\u2013817","journal-title":"Mol Psychiatry"},{"key":"16_CR171","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/0006-8993(85)90794-2","volume":"340","author":"SA Baron","year":"1985","unstructured":"Baron SA, Testa FM, Gintzler AR (1985) Simultaneous quantitation of norepinephrine, dopamine and serotonin in brain during and following chronic naltrexone administration. Brain Res 340:192\u2013198","journal-title":"Brain Res"},{"key":"16_CR172","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-1-4613-9000-8_11","volume-title":"Opioids, bulimia, and alcohol abuse & addiction","author":"JR Volpicelli","year":"1990","unstructured":"Volpicelli JR, O'Brien CP, Alterman AI, Hayashida M (1990) Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LD (ed) Opioids, bulimia, and alcohol abuse & addiction. Springe, New York, pp 195\u2013214"},{"key":"16_CR173","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876\u2013880","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR174","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O\u2019Malley","year":"1992","unstructured":"O\u2019Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49:881\u2013887","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR175","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1530-0277.1996.tb01679.x","volume":"20","author":"D Davidson","year":"1996","unstructured":"Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732\u2013739","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR176","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00019442-199700540-00007","volume":"5","author":"D Oslin","year":"1997","unstructured":"Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5:324\u2013332","journal-title":"Am J Geriatr Psychiatry"},{"key":"16_CR177","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","volume":"156","author":"RF Anton","year":"1999","unstructured":"Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156:1758\u20131764","journal-title":"Am J Psychiatry"},{"key":"16_CR178","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","volume":"35","author":"J Chick","year":"2000","unstructured":"Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35:587\u2013593","journal-title":"Alcohol Alcohol"},{"key":"16_CR179","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00004714-200106000-00006","volume":"21","author":"P Heinala","year":"2001","unstructured":"Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21:287\u2013292","journal-title":"J Clin Psychopharmacol"},{"key":"16_CR180","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1530-0277.2001.tb02170.x","volume":"25","author":"PM Monti","year":"2001","unstructured":"Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25:1634\u20131647","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR181","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1530-0277.2002.tb02682.x","volume":"26","author":"J Guardia","year":"2002","unstructured":"Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26:1381\u20131387","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR182","doi-asserted-by":"publisher","first-page":"530","DOI":"10.5694\/j.1326-5377.2002.tb04550.x","volume":"176","author":"NC Latt","year":"2002","unstructured":"Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176:530\u2013534","journal-title":"Med J Aust"},{"key":"16_CR183","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","volume":"27","author":"J Balldin","year":"2003","unstructured":"Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27:1142\u20131149","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR184","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"F Kiefer","year":"2003","unstructured":"Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92\u201399","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR185","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","volume":"22","author":"HR Kranzler","year":"2000","unstructured":"Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22:493\u2013503","journal-title":"Neuropsychopharmacology"},{"key":"16_CR186","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa011127","volume":"345","author":"JH Krystal","year":"2001","unstructured":"Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734\u20131739","journal-title":"N Engl J Med"},{"key":"16_CR187","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1176\/ajp.151.10.1463","volume":"151","author":"RM Swift","year":"1994","unstructured":"Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151:1463\u20131467","journal-title":"Am J Psychiatry"},{"key":"16_CR188","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1176\/ajp.152.4.613","volume":"152","author":"JR Volpicelli","year":"1995","unstructured":"Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP (1995) Effect of naltrexone on alcohol \"high\" in alcoholics. Am J Psychiatry 152:613\u2013615","journal-title":"Am J Psychiatry"},{"key":"16_CR189","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","volume":"28","author":"DJ Drobes","year":"2004","unstructured":"Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362\u20131370","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR190","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00213-003-1720-7","volume":"173","author":"RF Anton","year":"2004","unstructured":"Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004) Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology 173:32\u201340","journal-title":"Psychopharmacology"},{"key":"16_CR191","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0006-8993(94)91900-3","volume":"648","author":"SB Jaffe","year":"1994","unstructured":"Jaffe SB, Sobieszczyk S, Wardlaw SL (1994) Effect of opioid antagonism on beta-endorphin processing and proopiomelanocortin-peptide release in the hypothalamus. Brain Res 648:24\u201331","journal-title":"Brain Res"},{"key":"16_CR192","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002130100919","volume":"160","author":"S O'Malley","year":"2002","unstructured":"O'Malley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160:19\u201329","journal-title":"Psychopharmacology"},{"key":"16_CR193","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/archpsyc.64.9.1069","volume":"64","author":"LA Ray","year":"2007","unstructured":"Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64:1069\u20131077","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR194","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/j.1530-0277.2006.00156.x","volume":"30","author":"JE McGeary","year":"2006","unstructured":"McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30:1288\u20131296","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR195","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","volume":"28","author":"DW Oslin","year":"2003","unstructured":"Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546\u20131552","journal-title":"Neuropsychopharmacology"},{"key":"16_CR196","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton RF, Oroszi G, O\u2019Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135\u2013144","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR197","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/npp.2011.192","volume":"37","author":"LA Ray","year":"2012","unstructured":"Ray LA, Bujarski S, Chin PF, Miotto K (2012) Pharmacogenetics of naltrexone in Asian Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology 37:445\u2013455","journal-title":"Neuropsychopharmacology"},{"key":"16_CR198","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1530-0277.2011.01446.x","volume":"35","author":"E Setiawan","year":"2011","unstructured":"Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C, Leyton M (2011) The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res 35:1134\u20131141","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR199","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00213-008-1330-5","volume":"201","author":"SG Kim","year":"2009","unstructured":"Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW (2009) A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 201:611\u2013618","journal-title":"Psychopharmacology"},{"key":"16_CR200","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/FPC.0b013e32834c5445","volume":"21","author":"JK Coller","year":"2011","unstructured":"Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM (2011) OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics 21:902\u2013905","journal-title":"Pharmacogenet Genomics"},{"key":"16_CR201","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1530-0277.2008.00846.x","volume":"33","author":"G Oroszi","year":"2009","unstructured":"Oroszi G, Anton RF, O'Malley S, Swift R, Pettinati H, Couper D, Yuan Q, Goldman D (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383\u2013393","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"16_CR202","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/npp.2011.192","volume":"37","author":"LA Ray","year":"2011","unstructured":"Ray LA, Bujarski S, Chin PF, Miotto K (2011) Pharmacogenetics of naltrexone in Asian Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology 37(2):445\u2013455","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"16_CR203","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","volume":"32","author":"SS O\u2019Malley","year":"2008","unstructured":"O\u2019Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V (2008) Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res 32(7):1271\u20131283","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"16_CR204","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1530-0277.2007.00545.x","volume":"32","author":"JW Tidey","year":"2008","unstructured":"Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S (2008) Moderators of naltrexone\u2019s effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32(1):58\u201366","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"16_CR205","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1530-0277.2007.00339.x","volume":"31","author":"J Gelernter","year":"2007","unstructured":"Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, V.A.C.S.S. Group (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31(4):555\u2013563","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR206","doi-asserted-by":"publisher","first-page":"RC110","DOI":"10.1523\/JNEUROSCI.20-22-j0007.2000","volume":"20","author":"I Gomes","year":"2000","unstructured":"Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA (2000) Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci 20:RC110","journal-title":"J Neurosci"},{"key":"16_CR207","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.neuroscience.2005.03.065","volume":"135","author":"N Hirose","year":"2005","unstructured":"Hirose N, Murakawa K, Takada K, Oi Y, Suzuki T, Nagase H, Cools AR, Koshikawa N (2005) Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Neuroscience 135:213\u2013225","journal-title":"Neuroscience"},{"key":"16_CR208","doi-asserted-by":"publisher","first-page":"ra54","DOI":"10.1126\/scisignal.2000807","volume":"3","author":"A Gupta","year":"2010","unstructured":"Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, Lim M, Maillet E, Junek M, Cahill CM, Harkany T, Devi LA (2010) Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 3:ra54","journal-title":"Sci Signal"},{"key":"16_CR209","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.mp.4002035","volume":"13","author":"H Zhang","year":"2008","unstructured":"Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J (2008) The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 13:531\u2013543","journal-title":"Mol Psychiatry"},{"key":"16_CR210","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1097\/00001756-199707280-00025","volume":"8","author":"P Mayer","year":"1997","unstructured":"Mayer P, Rochlitz H, Rauch E, Rommelspacher H, Hasse HE, Schmidt S, Hollt V (1997) Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 8:2547\u20132550","journal-title":"Neuroreport"},{"key":"16_CR211","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1601-183X.2008.00410.x","volume":"7","author":"O Levran","year":"2008","unstructured":"Levran O, Londono D, O'Hara K, Nielsen DA, Peles E, Rotrosen J, Casadonte P, Linzy S, Randesi M, Ott J, Adelson M, Kreek MJ (2008) Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 7:720\u2013729","journal-title":"Genes Brain Behav"},{"issue":"1","key":"16_CR212","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41398-021-01439-y","volume":"11","author":"O Levran","year":"2021","unstructured":"Levran O, Randesi M, Adelson M, Kreek MJ (2021) OPRD1 SNPs associated with opioid addiction are cis-eQTLs for the phosphatase and actin regulator 4 gene, PHACTR4, a mediator of cytoskeletal dynamics. Transl Psychiatry 11(1):316","journal-title":"Transl Psychiatry"},{"issue":"10","key":"16_CR213","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/npp.2013.99","volume":"38","author":"RC Crist","year":"2013","unstructured":"Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH (2013) An Intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 38(10):2003\u20132010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"16_CR214","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1369-1600.2012.00445.x","volume":"19","author":"EC Nelson","year":"2014","unstructured":"Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, Shand FL, Henders AK, Wallace L, Todorov AA, Schrage AJ, Madden PA, Degenhardt L, Martin NG, Montgomery GW (2014) Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol 19(1):111\u2013121","journal-title":"Addict Biol"},{"key":"16_CR215","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/76061","volume":"25","author":"D Filliol","year":"2000","unstructured":"Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195\u2013200","journal-title":"Nat Genet"},{"key":"16_CR216","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0896-6273(00)80836-3","volume":"24","author":"Y Zhu","year":"1999","unstructured":"Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24:243\u2013252","journal-title":"Neuron"},{"key":"16_CR217","doi-asserted-by":"publisher","first-page":"10906","DOI":"10.1523\/JNEUROSCI.22-24-10906.2002","volume":"22","author":"JF Nitsche","year":"2002","unstructured":"Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE (2002) Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22:10906\u201310913","journal-title":"J Neurosci"},{"key":"16_CR218","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/syn.890150104","volume":"15","author":"EM Unterwald","year":"1993","unstructured":"Unterwald EM, Cox BM, Kreek MJ, Cote TE, Izenwasser S (1993) Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse 15:33\u201338","journal-title":"Synapse"},{"issue":"3","key":"16_CR219","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41397-018-0065-x","volume":"19","author":"RC Crist","year":"2019","unstructured":"Crist RC, Phillips KA, Furnari MA, Moran LM, Doyle GA, McNicholas LF, Cornish JW, Kampman KM, Preston KL, Berrettini WH (2019) Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder. Pharmacogenomics J 19(3):260\u2013268","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"16_CR220","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.bbrc.2014.06.099","volume":"450","author":"N Kabli","year":"2014","unstructured":"Kabli N, Fan T, O'Dowd BF, George SR (2014) Mu-delta opioid receptor heteromer-specific signaling in the striatum and hippocampus. Biochem Biophys Res Commun 450(1):906\u2013911","journal-title":"Biochem Biophys Res Commun"},{"key":"16_CR221","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00018-011-0844-x","volume":"69","author":"HA Tejeda","year":"2012","unstructured":"Tejeda HA, Shippenberg TS, Henriksson R (2012) The dynorphin\/kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69:857\u2013896","journal-title":"Cell Mol Life Sci"},{"key":"16_CR222","first-page":"113","volume":"174","author":"LH Claye","year":"1997","unstructured":"Claye LH, Maisonneuve IM, Yu J, Ho A, Kreek MJ (1997) Local perfusion of dynorphin A 1-17 reduces extracellular dopamine levels in the nucleus accumbens. NIDA Res Monogr 174:113","journal-title":"NIDA Res Monogr"},{"key":"16_CR223","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00213-003-1716-3","volume":"173","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2004) Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice. Psychopharmacology 173:146\u2013152","journal-title":"Psychopharmacology"},{"key":"16_CR224","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/00001756-199408150-00018","volume":"5","author":"EM Unterwald","year":"1994","unstructured":"Unterwald EM, Rubenfeld JM, Kreek MJ (1994) Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5:1613\u20131616","journal-title":"Neuroreport"},{"key":"16_CR225","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/emboj\/17.4.886","volume":"17","author":"F Simonin","year":"1998","unstructured":"Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17:886\u2013897","journal-title":"EMBO J"},{"key":"16_CR226","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","volume":"23","author":"JP McLaughlin","year":"2003","unstructured":"McLaughlin JP, Marton-Popovici M, Chavkin C (2003) Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674\u20135683","journal-title":"J Neurosci"},{"key":"16_CR227","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/00952990802122564","volume":"34","author":"CN Haile","year":"2008","unstructured":"Haile CN, Kosten TA, Kosten TR (2008) Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 34:355\u2013381","journal-title":"Am J Drug Alcohol Abuse"},{"key":"16_CR228","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/sj.mp.4001882","volume":"11","author":"X Xuei","year":"2006","unstructured":"Xuei X, Dick D, Flury-Wetherill L, Tian HJ, Agrawal A, Bierut L, Goate A, Bucholz K, Schuckit M, Nurnberger J Jr, Tischfield J, Kuperman S, Porjesz B, Begleiter H, Foroud T, Edenberg HJ (2006) Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 11:1016\u20131024","journal-title":"Mol Psychiatry"},{"issue":"2","key":"16_CR229","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JCP.0000000000000082","volume":"34","author":"SC Wang","year":"2014","unstructured":"Wang SC, Tsou HH, Chung RH, Chang YS, Fang CP, Chen CH, Ho K, Kuo HW, Liu SC, Shih YH (2014) The association of genetic polymorphisms in the \u03ba-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J Clin Psychopharmacol 34(2):205\u2013211","journal-title":"J Clin Psychopharmacol"},{"key":"16_CR230","doi-asserted-by":"crossref","unstructured":"Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J (2008) The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 13(5):531\u2013543","DOI":"10.1038\/sj.mp.4002035"},{"issue":"8","key":"16_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.62","volume":"3","author":"K Xu","year":"2013","unstructured":"Xu K, Seo D, Hodgkinson C, Hu Y, Goldman D, Sinha R (2013) A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. Transl Psychiatry 3(8):e292","journal-title":"Transl Psychiatry"},{"key":"16_CR232","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/YPG.0000000000000008","volume":"23","author":"DA Nielsen","year":"2013","unstructured":"Nielsen DA, Hamon S, Kosten TR (2013) The K-opioid receptor gene as a predictor of response in a cocaine vaccine trial. Psychiatr Genet 23:225\u2013232","journal-title":"Psychiatr Genet"},{"issue":"5292","key":"16_CR233","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","volume":"274","author":"KP Lesch","year":"1996","unstructured":"Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292):1527\u20131531","journal-title":"Science"},{"issue":"6","key":"16_CR234","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1046\/j.1471-4159.1996.66062621.x","volume":"66","author":"A Heils","year":"1996","unstructured":"Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66(6):2621\u20132624","journal-title":"J Neurochem"},{"issue":"5","key":"16_CR235","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1086\/503850","volume":"78","author":"XZ Hu","year":"2006","unstructured":"Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78(5):815\u2013826","journal-title":"Am J Hum Genet"},{"issue":"4","key":"16_CR236","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.biopsych.2006.09.022","volume":"62","author":"N Praschak-Rieder","year":"2007","unstructured":"Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, Ginovart N, Tharmalingam S, Masellis M, Houle S, Meyer JH (2007) Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry 62(4):327\u2013331","journal-title":"Biol Psychiatry"},{"issue":"11","key":"16_CR237","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.biopsych.2011.07.004","volume":"70","author":"E Fox","year":"2011","unstructured":"Fox E, Zougkou K, Ridgewell A, Garner K (2011) The serotonin transporter gene alters sensitivity to attention bias modification: evidence for a plasticity gene. Biol Psychiatry 70(11):1049\u20131054","journal-title":"Biol Psychiatry"},{"issue":"6","key":"16_CR238","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.37","volume":"4","author":"M Wankerl","year":"2014","unstructured":"Wankerl M, Miller R, Kirschbaum C, Hennig J, Stalder T, Alexander N (2014) Effects of genetic and early environmental risk factors for depression on serotonin transporter expression and methylation profiles. Transl Psychiatry 4(6):e402","journal-title":"Transl Psychiatry"},{"issue":"6","key":"16_CR239","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jpsychires.2013.02.006","volume":"47","author":"DP Graham","year":"2013","unstructured":"Graham DP, Helmer DA, Harding MJ, Kosten TR, Petersen NJ, Nielsen DA (2013) Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans. J Psychiatr Res 47(6):835\u2013842","journal-title":"J Psychiatr Res"},{"key":"16_CR240","first-page":"1174","volume":"19","author":"Y Gonz\u00e1lez-Giraldo","year":"2020","unstructured":"Gonz\u00e1lez-Giraldo Y, Forero DA (2020) Association between resilience and a functional polymorphism in the serotonin transporter (SCL6A4) gene: A meta-analysis. EXCLI J 19:1174\u20131183","journal-title":"EXCLI J"},{"issue":"7","key":"16_CR241","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrn1925","volume":"7","author":"A Caspi","year":"2006","unstructured":"Caspi A, Moffitt TE (2006) Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7(7):583\u2013590","journal-title":"Nat Rev Neurosci"},{"key":"16_CR242","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-1-0716-0947-7_13","volume":"2212","author":"F Zhou","year":"2021","unstructured":"Zhou F, Ren J, Lu X, Ma S, Wu C (2021) Gene-environment interaction: a variable selection perspective. Methods Mol Biol 2212:191\u2013223","journal-title":"Methods Mol Biol"},{"key":"16_CR243","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.neuro.051508.135335","volume":"32","author":"AR Hariri","year":"2009","unstructured":"Hariri AR (2009) The neurobiology of individual differences in complex behavioral traits. Annu Rev Neurosci 32:225\u2013247","journal-title":"Annu Rev Neurosci"},{"issue":"12","key":"16_CR244","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/mp.2009.85","volume":"14","author":"R Uher","year":"2009","unstructured":"Uher R (2009) The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol Psychiatry 14(12):1072\u20131082","journal-title":"Mol Psychiatry"},{"issue":"9","key":"16_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.88","volume":"4","author":"N Alexander","year":"2014","unstructured":"Alexander N, Wankerl M, Hennig J, Miller R, Zankert S, Steudte-Schmiedgen S, Stalder T, Kirschbaum C (2014) DNA methylation profiles within the serotonin transporter gene moderate the association of 5-HTTLPR and cortisol stress reactivity. Transl Psychiatry 4(9):e443","journal-title":"Transl Psychiatry"},{"issue":"5","key":"16_CR246","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4088\/JCP.15m10596","volume":"78","author":"SAM Rauch","year":"2017","unstructured":"Rauch SAM, King AP, Liberzon I, Sripada RK (2017) Changes in salivary cortisol during psychotherapy for posttraumatic stress disorder: a pilot study in 30 veterans. J Clin Psychiatry 78(5):599\u2013603","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"16_CR247","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2174\/1389202919666171228164350","volume":"19","author":"PZ Liu","year":"2018","unstructured":"Liu PZ, Nusslock R (2018) How stress gets under the skin: early life adversity and glucocorticoid receptor epigenetic regulation. Curr Genomics 19(8):653\u2013664","journal-title":"Curr Genomics"},{"issue":"16","key":"16_CR248","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1002\/hbm.25138","volume":"41","author":"M Spies","year":"2020","unstructured":"Spies M, Nasser A, Ozenne B, Jensen PS, Knudsen GM, Fisher PM (2020) Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels. Hum Brain Mapp 41(16):4518\u20134528","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"16_CR249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.09.004","volume":"78","author":"M Torrens","year":"2005","unstructured":"Torrens M, Fonseca F, Mateu G, Farre M (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 78(1):1\u201322","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"16_CR250","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/13556210500235540","volume":"10","author":"P Mannelli","year":"2005","unstructured":"Mannelli P, Patkar AA, Murray HW, Certa K, Peindl K, Mattila-Evenden M, Berrettini WH (2005) Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals. Addict Biol 10(3):261\u2013268","journal-title":"Addict Biol"},{"issue":"8","key":"16_CR251","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1601-183X.2012.00839.x","volume":"11","author":"DA Nielsen","year":"2012","unstructured":"Nielsen DA, Harding MJ, Hamon SC, Huang W, Kosten TR (2012) Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes Brain Behav 11(8):1001\u20131008","journal-title":"Genes Brain Behav"},{"issue":"1","key":"16_CR252","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0197-0186(93)90065-D","volume":"22","author":"SN Nagendra","year":"1993","unstructured":"Nagendra SN, Shetty KT, Subhash MN, Udaya HB, Pradhan N (1993) Effect of disulfiram administration on brain tryptophan, serotonin and peripheral tryptophan content. Neurochem Int 22(1):31\u201336","journal-title":"Neurochem Int"},{"issue":"6","key":"16_CR253","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/BF00964915","volume":"14","author":"GE Nilsson","year":"1989","unstructured":"Nilsson GE, Tottmar O (1989) Effects of disulfiram and coprine on rat brain tryptophan hydroxylation in vivo. Neurochem Res 14(6):537\u2013540","journal-title":"Neurochem Res"},{"key":"16_CR254","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0014-2999(80)90166-1","volume":"61","author":"R Fukumori","year":"1980","unstructured":"Fukumori R, Minegishi A, Satoh T, Kitagawa H, Yanaura S (1980) Changes in the serotonin and 5-hydroxyindoleacetic acid contents in rat brain after ethanol and disulfiram treatments. Eur J Pharmacol 61:199\u2013202","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"16_CR255","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/pgs.15.72","volume":"16","author":"IE Bauer","year":"2015","unstructured":"Bauer IE, Graham DP, Soares JC, Nielsen DA (2015) Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics 16(11):1307\u20131314","journal-title":"Pharmacogenomics"},{"issue":"8","key":"16_CR256","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jama.284.8.963","volume":"284","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 284(8):963\u2013971","journal-title":"JAMA"},{"issue":"3","key":"16_CR257","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","volume":"168","author":"BA Johnson","year":"2011","unstructured":"Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168(3):265\u2013275","journal-title":"Am J Psychiatry"},{"key":"16_CR258","first-page":"23","volume":"3","author":"C Seneviratne","year":"2012","unstructured":"Seneviratne C, Johnson BA (2012) Serotonergic genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics. Front Psych 3:23","journal-title":"Front Psych"},{"issue":"1","key":"16_CR259","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JCP.0b013e31820465fa","volume":"31","author":"HR Kranzler","year":"2011","unstructured":"Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C (2011) A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 31(1):22\u201330","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"16_CR260","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1530-0277.2011.01659.x","volume":"36","author":"HR Kranzler","year":"2012","unstructured":"Kranzler HR, Armeli S, Tennem H (2012) Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcohol Clin Exp Res 36(4):739\u2013744","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"16_CR261","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11920-012-0296-5","volume":"14","author":"HR Kranzler","year":"2012","unstructured":"Kranzler HR, McKay JR (2012) Personalized treatment of alcohol dependence. Curr Psychiatry Rep 14(5):486\u2013493","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"16_CR262","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1530-0277.2008.00835.x","volume":"33","author":"GA Kenna","year":"2009","unstructured":"Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM (2009) A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 33(2):315\u2013323","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"16_CR263","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/00952990.2017.1420795","volume":"44","author":"RC Crist","year":"2018","unstructured":"Crist RC, Li J, Doyle GA, Gilbert A, Dechairo BM, Berrettini WH (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44(4):431\u2013440","journal-title":"Am J Drug Alcohol Abuse"},{"key":"16_CR264","first-page":"265","volume":"132","author":"JR Cooper","year":"1961","unstructured":"Cooper JR, Melcer I (1961) The enzymatic oxidation of tryptophan to 5-hydroxytryptophan in the biosynthesis of serotonin. J Pharmacol Exp Ther 132:265\u2013268","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"16_CR265","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jpsychires.2005.05.004","volume":"41","author":"P Zill","year":"2007","unstructured":"Zill P, B\u00fcttner A, Eisenmenger W, Moller HJ, Ackenheil M, Bondy B (2007) Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study. J Psychiatr Res 41(1\u20132):168\u2013173","journal-title":"J Psychiatr Res"},{"issue":"5","key":"16_CR266","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/ijms22052452","volume":"22","author":"S Park","year":"2021","unstructured":"Park S, Kim Y, Lee J, Lee JY, Kim H, Lee S, Oh CM (2021) A systems biology approach to investigating the interaction between serotonin synthesis by tryptophan hydroxylase and the metabolic homeostasis. Int J Mol Sci 22(5):2452","journal-title":"Int J Mol Sci"},{"issue":"3","key":"16_CR267","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.psyneuen.2010.12.012","volume":"36","author":"J Waider","year":"2011","unstructured":"Waider J, Araragi N, Gutknecht L, Lesch KP (2011) Tryptophan hydroxylase-2 (TPH2) in disorders of cognitive control and emotion regulation: a perspective. Psychoneuroendocrinology 36(3):393\u2013405","journal-title":"Psychoneuroendocrinology"},{"key":"16_CR268","doi-asserted-by":"publisher","unstructured":"Deneris E, Gaspar P (2018) Serotonin neuron development: shaping molecular and structural identities. Wiley Interdiscip Rev Dev Biol 7(1). https:\/\/doi.org\/10.1002\/wdev.301","DOI":"10.1002\/wdev.301"},{"issue":"2","key":"16_CR269","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10519-007-9187-7","volume":"38","author":"DA Nielsen","year":"2008","unstructured":"Nielsen DA, Barral S, Proudnikov D, Kellogg S, Ho A, Ott J, Kreek MJ (2008) TPH2 and TPH1: association of variants and interactions with heroin addiction. Behav Genet 38(2):133\u2013150","journal-title":"Behav Genet"},{"issue":"5","key":"16_CR270","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/sj.mp.4001923","volume":"12","author":"JE Lim","year":"2007","unstructured":"Lim JE, Pinsonneault J, Sadee W, Saffen D (2007) Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatry 12(5):491\u2013501","journal-title":"Mol Psychiatry"},{"issue":"4","key":"16_CR271","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/jpm11040259","volume":"11","author":"CL Huang","year":"2021","unstructured":"Huang CL, Chen PH, Lane HY, Ho IK, Chung CM (2021) Risk assessment for heroin use and craving score using polygenic risk score. J Pers Med 11(4):259","journal-title":"J Pers Med"},{"issue":"2","key":"16_CR272","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-0854.2006.00515.x","volume":"8","author":"F Berditchevski","year":"2007","unstructured":"Berditchevski F, Odintsova E (2007) Tetraspanins as regulators of protein trafficking. Traffic 8(2):89\u201396","journal-title":"Traffic"},{"issue":"12","key":"16_CR273","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/mp.2016.6","volume":"21","author":"M Gupta","year":"2016","unstructured":"Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM (2016) TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry 21(12):1714\u20131725","journal-title":"Mol Psychiatry"},{"key":"16_CR274","doi-asserted-by":"publisher","unstructured":"Ho MF, Zhang C, Zhang L, Wei L, Zhou Y, Moon I, Geske JR, Choi DS, Biernacka J, Frye M, Wen Z, Karpyak VM, Li H, Weinshilboum R (2020) TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-020-0855-9","DOI":"10.1038\/s41380-020-0855-9"},{"key":"16_CR275","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000107104","volume":"80","author":"S Crettol","year":"2007","unstructured":"Crettol S, Digon P, Powell Golay K, Brawand M, Eap CB (2007) In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology 80:304\u2013311","journal-title":"Pharmacology"},{"key":"16_CR276","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bcp.2003.08.027","volume":"67","author":"C Dagenais","year":"2004","unstructured":"Dagenais C, Graff CL, Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269\u2013276","journal-title":"Biochem Pharmacol"},{"key":"16_CR277","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","volume":"17","author":"O Levran","year":"2008","unstructured":"Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17:2219\u20132227","journal-title":"Hum Mol Genet"},{"key":"16_CR278","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fgene.2018.00450","volume":"29","author":"S Peng","year":"2018","unstructured":"Peng S, Jiang H, Du J, Lin S, Pan S, Yu S, Zhao M (2018) Methadone dosage and plasma levels, SNPs of OPRM1 gene and age of first drug use were associated with outcomes of methadone maintenance treatment. Front Genet 29:450","journal-title":"Front Genet"},{"key":"16_CR279","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.clpt.2006.09.011","volume":"80","author":"JK Coller","year":"2006","unstructured":"Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA (2006) ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80:682\u2013690","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR280","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00414-021-02502-5","volume":"135","author":"S Iwerson-Bergmann","year":"2021","unstructured":"Iwerson-Bergmann S, Plattner S, Hischke S, M\u00fcller A, Andresen-Streichert H, Jungen H, Erb R, Beer-Sandner B (2021) Brain\/blood ratios of methadone and ABCB1 polymorphisms in methadone related deaths. Int J Legal Med 135:473\u2013482","journal-title":"Int J Legal Med"},{"key":"16_CR281","first-page":"53","volume":"5","author":"DT Barratt","year":"2012","unstructured":"Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJ, Somogyi AA (2012) ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics Pers Med 5:53\u201362","journal-title":"Pharmacogenomics Pers Med"},{"key":"16_CR282","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1744-9081-4-1","volume":"4","author":"C Guindalini","year":"2008","unstructured":"Guindalini C, Laranjeira R, Collier D, Messas G, Vallada H, Breen G (2008) Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav Brain Funct 4:1","journal-title":"Behav Brain Funct"},{"issue":"11","key":"16_CR283","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.euroneuro.2013.05.014","volume":"23","author":"D Shorter","year":"2013","unstructured":"Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR (2013) Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha-adrenoceptor gene variation. Eur Neuropsychopharmacol 23(11):1401\u20131407","journal-title":"Eur Neuropsychopharmacol"},{"key":"16_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135677","volume":"748","author":"C Deji","year":"2021","unstructured":"Deji C, Li Y, Chen Y, Jianghua L, Shuguang W (2021) Association study of catechol-o-methyltransferase and Alpha-1-adrenergic receptor gene polymorphisms with multiple phenotypes of heroin use disorder. Neurosci Lett 748:135677","journal-title":"Neurosci Lett"},{"key":"16_CR285","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrn3505","volume":"14","author":"B Lu","year":"2013","unstructured":"Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 14:401\u2013416","journal-title":"Nat Rev Neurosci"},{"key":"16_CR286","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027389","volume":"6","author":"E Rostami","year":"2011","unstructured":"Rostami E, Krueger F, Zoubak S, Dal Monte O, Raymont V, Pardini M, Hodgkinson CA, Goldman D, Risling M, Grafman J (2011) BDNF polymorphism predicts general intelligence after penetrating traumatic brain injury. PLoS One 6:e27389","journal-title":"PLoS One"},{"key":"16_CR287","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ajmg.b.32183","volume":"162","author":"W Li","year":"2013","unstructured":"Li W, Zhou N, Yu Q, Li X, Yu Y, Sun S, Kou C, Chen da C, Xiu MH, Kosten TR, Zhang XY (2013) Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 162:538\u2013545","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"16_CR288","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.molbrainres.2005.07.008","volume":"140","author":"CY Cheng","year":"2005","unstructured":"Cheng CY, Hong CJ, Yu YWY, Chen TJ, Wu HC, Tsai SJ (2005) Brain-derived neurotropic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol 140:86\u201390","journal-title":"Brain Res Mol"},{"key":"16_CR289","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1369-1600.2011.00431.x","volume":"18","author":"MK Greenwald","year":"2013","unstructured":"Greenwald MK, Steinmiller CL, Sliwerska E, Lundahl L, Burmeister M (2013) BDNF Val(66)met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals; a pilot study. Addict Biol 18:836\u2013845","journal-title":"Addict Biol"},{"key":"16_CR290","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1601-183X.2007.00386.x","volume":"7","author":"R de Cid","year":"2008","unstructured":"de Cid R, Fonseca F, Gratacos M, Gutierrez F, Martin-Santos R, Estivill X, Torrens M (2008) BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav 7:515\u2013522","journal-title":"Genes Brain Behav"},{"key":"16_CR291","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","volume":"29","author":"S Pezet","year":"2006","unstructured":"Pezet S, McMahon SB (2006) Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29:507\u2013538","journal-title":"Annu Rev Neurosci"},{"key":"16_CR292","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/tpj.2011.6","volume":"12","author":"O Levran","year":"2012","unstructured":"Levran O, Peles E, Hamon S, Randesi M, Zhao C, Zhang B, Adelson M, Kreek MJ (2012) Nerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. Pharmacogenomics J 12:319\u2013327","journal-title":"Pharmacogenomics J"},{"key":"16_CR293","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev.neuro.27.070203.144206","volume":"27","author":"RR Gainetdinov","year":"2004","unstructured":"Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107\u2013144","journal-title":"Annu Rev Neurosci"},{"key":"16_CR294","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/tpj.2010.37","volume":"11","author":"B Oneda","year":"2011","unstructured":"Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R, Monnat M, Preisig M, Eap CB (2011) \u03b2-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J 11:258\u2013266","journal-title":"Pharmacogenomics J"},{"key":"16_CR295","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/ajad.13150","volume":"30","author":"KK Karavidha","year":"2021","unstructured":"Karavidha KK, Burmeister M, Greenwald MK (2021) \u03b2-Arrestin 2 (ARRB2) polymorphism is associated with adverse consequences of chronic heroin use. Am J Addict 30:351\u2013357","journal-title":"Am J Addict"},{"key":"16_CR296","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CP, Bertolini A, Sternieri E (2004) Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551\u2013559","journal-title":"Pharmacol Res"},{"key":"16_CR297","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cll.2008.10.003","volume":"28","author":"KK Reynolds","year":"2008","unstructured":"Reynolds KK, Ramey-Hartung B, Jortani SA (2008) The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med 28:581\u2013598","journal-title":"Clin Lab Med"},{"key":"16_CR298","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.drugalcdep.2006.12.018","volume":"89","author":"J Perez de los Cobos","year":"2007","unstructured":"Perez de los Cobos J, Sinol N, Trujols J, del Rio E, Banuls E, Luquero E, Menoyo A, Queralto JM, Baiget M, Alvarez E (2007) Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 89:190\u2013194","journal-title":"Drug Alcohol Depend"},{"key":"16_CR299","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","volume":"80","author":"S Crettol","year":"2006","unstructured":"Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668\u2013681","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR300","first-page":"179","volume":"11","author":"C Dagostino","year":"2018","unstructured":"Dagostino C, Allegri M, Napolioni V, D\u2019Agnelli S, Bignami E, Mutti A, van Schalk RHN (2018) CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic lower back pain: results from a retrospective study in an Italian cohort. Pharmacogenomics Pers Med 11:179\u2013191","journal-title":"Pharmacogenomics Pers Med"},{"issue":"5","key":"16_CR301","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/pgs-2020-0143","volume":"22","author":"NN Umukoro","year":"2021","unstructured":"Umukoro NN, Aruldhas BW, Rossos R, Pawale D, Renschler JS, Sadhasivam S (2021) Pharmacogenomics of oxycodone: a narrative literature review. Pharmacogenomics 22(5):275\u2013290","journal-title":"Pharmacogenomics"},{"key":"16_CR302","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","volume":"18","author":"O Levran","year":"2013","unstructured":"Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ (2013) CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 18:709\u2013716","journal-title":"Addict Biol"},{"key":"16_CR303","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","volume":"78","author":"S Crettol","year":"2005","unstructured":"Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593\u2013604","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR304","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","volume":"23","author":"M Dobrinas","year":"2013","unstructured":"Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, Eap CB (2013) Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics 23:84\u201393","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"16_CR305","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jat\/bkw135","volume":"41","author":"T Ahmad","year":"2017","unstructured":"Ahmad T, Sabet S, Primerano D, Richards-Waugh L, Rankin GO (2017) Tell-tale SNPs: the role of CYP2B6 in methadone fatalities. J Anal Toxicol 41(4):325\u2013333","journal-title":"J Anal Toxicol"},{"issue":"12","key":"16_CR306","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/add.14373","volume":"113","author":"KC Morley","year":"2018","unstructured":"Morley KC, Luquin N, Baillie A, Fraser I, Trent RJ, Dore G, Phung N, Haber PS (2018) Moderation of baclofen response by a BABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction 113(12):2205\u20132213","journal-title":"Addiction"},{"key":"16_CR307","doi-asserted-by":"publisher","first-page":"E50","DOI":"10.1152\/ajpendo.00274.2001","volume":"283","author":"Q He","year":"2002","unstructured":"He Q, Mendez M, LaPointe MC (2002) Regulation of the human brain natriuretic peptide gene by GATA-4. Am J Physiol Endocrinol Metab 283:E50\u2013E57","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"16_CR308","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2174\/0929867033456459","volume":"10","author":"GL Kovacs","year":"2003","unstructured":"Kovacs GL (2003) Natriuretic peptides in alcohol withdrawal: central and peripheral mechanisms. Curr Med Chem 10:2559\u20132576","journal-title":"Curr Med Chem"},{"key":"16_CR309","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/tpj.2010.51","volume":"11","author":"F Kiefer","year":"2011","unstructured":"Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, Nothen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedemann K, Smolka MN, Heinz A, Rietschel M, Mann K (2011) Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 11:368\u2013374","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"16_CR310","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1369-1600.2012.00482.x","volume":"19","author":"VM Karpyak","year":"2012","unstructured":"Karpyak VM, Winham SJ, Biernacka JM, Cunningham JM, Lewis KA, Geske JR, Colby CL, Abulseoud OA, Hall-Flavin DK, Loukianova LL, Schneekloth TD, Frye MA, Heit JA, Mrazek DA (2012) Association of GATA4 sequence variation with alcohol dependence. Addict Biol 19(2):312\u2013315","journal-title":"Addict Biol"},{"key":"16_CR311","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archgenpsychiatry.2009.83","volume":"66","author":"J Treutlein","year":"2009","unstructured":"Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka M, Zill P, Maier W, Moessner R, Gaebel W, Dahmen N, Fehr C, Scherbaum N, Steffens M, Ludwig KU, Frank J, Wichmann HE, Schreiber S, Dragano N, Sommer WH, Leonardi-Essmann F, Lourdusamy A, Gebicke-Haerter P, Wienker TF, Sullivan PF, Nothen MM, Kiefer F, Spanagel R, Mann K, Rietschel M (2009) Genome-wide association study of alcohol dependence. Arch Gen Psychiatry 66:773\u2013784","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR312","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM (2014) Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445\u2013452","journal-title":"Am J Psychiatry"},{"key":"16_CR313","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1111\/acer.12578","volume":"38","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J (2014) Posttreatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res 38:3017\u20133023","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"16_CR314","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/acer.14399","volume":"44","author":"R Lieberman","year":"2020","unstructured":"Lieberman R, Jensen KP, Clinton K, Levine ES, Kranzler HR, Covault J (2020) Molecular correlates of topiramate and GRIK1 rs2832407 genotype in pluripotent stem cell-derived neural cultures. Alcohol Clin Exp Res 44(8):1561\u20131570","journal-title":"Alcohol Clin Exp Res"},{"key":"16_CR315","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"P Frosst","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111\u2013113","journal-title":"Nat Genet"},{"key":"16_CR316","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0140-6736(95)91743-8","volume":"346","author":"NM van der Put","year":"1995","unstructured":"van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070\u20131071","journal-title":"Lancet"},{"key":"16_CR317","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3171\/2010.8.PEDS1072","volume":"6","author":"PN Harisha","year":"2010","unstructured":"Harisha PN, Devi BI, Christopher R, Kruthika-Vinod TP (2010) Impact of 5,10-methylenetetrahydrofolate reductase gene polymorphism on neural tube defects. J Neurosurg Pediatr 6:364\u2013367","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"16_CR318","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/01.ALC.0000156083.91214.59","volume":"29","author":"S Bleich","year":"2005","unstructured":"Bleich S, Carl M, Bayerlein K, Reulbach U, Biermann T, Hillemacher T, B\u00f6nsch D, Kornhuber J (2005) Evidence of increased homocysteine levels in alcoholism: the Franconian alcoholism research studies (FARS). Alcohol Clin Exp Res 29(3):334\u2013336","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"16_CR319","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1530-0277.2006.00242.x","volume":"30","author":"UC Lutz","year":"2006","unstructured":"Lutz UC, Batra A, Kolb W, Machicao F, Maurer S, K\u00f6hnke MD (2006) Methylenetetrahydrofolate reductase C677T-polymorphism and its association with alcohol withdrawal seizure. Alcohol Clin Exp Res 30(12):1966\u20131971","journal-title":"Alcohol Clin Exp Res"},{"issue":"1\u20132","key":"16_CR320","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugalcdep.2008.01.016","volume":"96","author":"R Saffroy","year":"2008","unstructured":"Saffroy R, Benyamina A, Pham P, Marill C, Karila L, Reffas M, Debuire B, Reynaud M, Lemoine A (2008) Protective effect against alcohol dependence of the thermolabile variant of MTHFR. Drug Alcohol Depend 96(1\u20132):30\u201336","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"16_CR321","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1369-1600.2009.00169.x","volume":"14","author":"A Benyamina","year":"2009","unstructured":"Benyamina A, Saffroy R, Blecha L, Pham P, Karila L, Debuire B, Lemoine A, Reynaud M (2009) Association between MTHFR 677C-T polymorphism and alcohol dependence according to Lesch and Babor typology. Addict Biol 14(4):503\u2013505","journal-title":"Addict Biol"},{"key":"16_CR322","first-page":"109","volume":"3","author":"CJ Spellicy","year":"2012","unstructured":"Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA (2012) The MTHFR C677T variant is associated with responsiveness to disulfiram treatment for cocaine dependency. Front Psych 3:109","journal-title":"Front Psych"},{"key":"16_CR323","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/pros.21247","volume":"71","author":"J Lin","year":"2011","unstructured":"Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA (2011) Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 71:333\u2013343","journal-title":"Prostate"},{"key":"16_CR324","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/npp.2010.128","volume":"35","author":"K Anier","year":"2010","unstructured":"Anier K, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A (2010) DNA methylation regulates cocaine-induced behavioral sensitization in mice. Neuropsychopharmacology 35:2450\u20132461","journal-title":"Neuropsychopharmacology"},{"key":"16_CR325","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1101\/gad.1428006","volume":"20","author":"GC Pipes","year":"2006","unstructured":"Pipes GC, Creemers EE, Olson EN (2006) The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 20:1545\u20131556","journal-title":"Genes Dev"},{"key":"16_CR326","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.mp.4002147","volume":"13","author":"DA Nielsen","year":"2008","unstructured":"Nielsen DA, Ji F, Yuferov V, Ho A, Chen A, Levran O, Ott J, Kreek MJ (2008) Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry 13:417\u2013428","journal-title":"Mol Psychiatry"},{"key":"16_CR327","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF03256370","volume":"14","author":"F Fonseca","year":"2010","unstructured":"Fonseca F, Gratacos M, Escaramis G, De Cid R, Martin-Santos R, Fernandez-Espejo E, Estivill X, Torrens M (2010) Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther 14:171\u2013178","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"16_CR328","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1159\/000108103","volume":"27","author":"J Miyoshi","year":"2007","unstructured":"Miyoshi J, Takai Y (2007) Nectin and nectin-like molecules: biology and pathology. Am J Nephrol 27(6):590\u2013604","journal-title":"Am J Nephrol"},{"issue":"6","key":"16_CR329","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234549","volume":"15","author":"CP Fang","year":"2020","unstructured":"Fang CP, Liu TH, Chung RH, Tsou HH, Kuo HW, Wang SC, Liu CC, Liu SC, Chen ACH, Liu YL (2020) Genetic variants in NECTIN4 encoding an adhesion molecule are associated with continued opioid use. PLoS One 15(6):e0234549","journal-title":"PLoS One"},{"key":"16_CR330","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1073\/pnas.0136822100","volume":"100","author":"I Mitrovic","year":"2003","unstructured":"Mitrovic I, Margeta-Mitrovic M, Bader S, Stoffel M, Jan LY, Basbaum AI (2003) Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc Natl Acad Sci U S A 100:271\u2013276","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR331","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1002\/cne.23051","volume":"520","author":"S Reyes","year":"2012","unstructured":"Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos G, Halliday GM (2012) GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol 520:2591\u20132607","journal-title":"J Comp Neurol"},{"key":"16_CR332","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/npp.2010.247","volume":"36","author":"TK Clarke","year":"2011","unstructured":"Clarke TK, Laucht M, Ridinger M, Wodarz N, Rietschel M, Maier W, Lathrop M, Lourdusamy A, Zimmermann US, Desrivieres S, Schumann G (2011) KCNJ6 is associated with adult alcohol dependence and involved in gene x early life stress interactions in adolescent alcohol drinking. Neuropsychopharmacology 36:1142\u20131148","journal-title":"Neuropsychopharmacology"},{"key":"16_CR333","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/j.1471-4159.2004.02997.x","volume":"92","author":"CK Webb","year":"2005","unstructured":"Webb CK, McCudden CR, Willard FS, Kimple RJ, Siderovski DP, Oxford GS (2005) D2 dopamine receptor activation of potassium channels is selectively decoupled by Galpha-specific GoLoco motif peptides. J Neurochem 92:1408\u20131418","journal-title":"J Neurochem"},{"key":"16_CR334","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0168-0102(95)00933-K","volume":"23","author":"M Minami","year":"1995","unstructured":"Minami M, Satoh M (1995) Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 23:121\u2013145","journal-title":"Neurosci Res"},{"key":"16_CR335","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0168-0102(00)00144-9","volume":"38","author":"K Ikeda","year":"2000","unstructured":"Ikeda K, Kobayashi T, Kumanishi T, Niki H, Yano R (2000) Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia. Neurosci Res 38:113\u2013116","journal-title":"Neurosci Res"},{"key":"16_CR336","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007060","volume":"4","author":"D Nishizawa","year":"2009","unstructured":"Nishizawa D, Nagashima M, Katoh R, Satoh Y, Tagami M, Kasai S, Ogai Y, Han W, Hasegawa J, Shimoyama N, Sora I, Hayashida M, Ikeda K (2009) Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS One 4:e7060","journal-title":"PLoS One"},{"key":"16_CR337","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FPC.0b013e3283386bda","volume":"20","author":"J Lotsch","year":"2010","unstructured":"Lotsch J, Pruss H, Veh RW, Doehring A (2010) A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics 20:291\u2013297","journal-title":"Pharmacogenet Genomics"},{"key":"16_CR338","first-page":"13","volume":"115","author":"C Kamarajan","year":"2017","unstructured":"Kamarajan C, Pandey AK, Chorlian DB, Manz N, Stimus AT, Edenberg HJ, Wetherill L, Schuckit M, Wang JC, Kuperman S, Kramer J, Tischfield JA, Porjesz B (2017) A KCNJ6 gene polymorphism modulates theta oscillations during reward processing. Int J Psychol 115:13\u201323","journal-title":"Int J Psychol"},{"key":"16_CR339","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0165-0173(98)00056-3","volume":"29","author":"W Klimesch","year":"1999","unstructured":"Klimesch W (1999) EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res Brain Res Rev 29:169\u2013195","journal-title":"Brain Res Brain Res Rev"},{"key":"16_CR340","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0167-8760(00)00141-0","volume":"39","author":"E Basar","year":"2001","unstructured":"Basar E, Schurmann M, Sakowitz O (2001) The selectively distributed theta system: functions. Int J Psychophysiol 39:197\u2013212","journal-title":"Int J Psychophysiol"},{"key":"16_CR341","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1385\/NMM:5:1:085","volume":"5","author":"MJ Kreek","year":"2004","unstructured":"Kreek MJ, Nielsen DA, LaForge KS (2004) Genes associated with addiction: alcoholism, opiate, and cocaine addiction. NeuroMolecular Med 5:85\u2013108","journal-title":"NeuroMolecular Med"},{"key":"16_CR342","unstructured":"Kleiderer E, Rice J, Conquest V, Williams J (1945) Pharmaceutical activities at the I.G. Farbenindustrie plant, Hochst am Main. (Commerce, O. o. t. P. B. D. o., Ed.), Washington, DC"},{"key":"16_CR343","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/187152710790966641","volume":"9","author":"BJ Mason","year":"2010","unstructured":"Mason BJ, Heyser CJ (2010) Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 9:23\u201332","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"12","key":"16_CR344","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1021\/acschemneuro.0c00254","volume":"11","author":"CN Kent","year":"2020","unstructured":"Kent CN, Park C, Lindsley CW (2020) Classics in chemical neuroscience: baclofen. ACS Chem Neurosci 11(12):1740\u20131755","journal-title":"ACS Chem Neurosci"},{"key":"16_CR345","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1046\/j.1360-0443.2000.95811734.x","volume":"95","author":"ME Jarvik","year":"2000","unstructured":"Jarvik ME, Caskey NH, Wirshing WC, Madsen DC, Iwamoto-Schaap PN, Elins JL, Eisenberger NI, Olmstead RE (2000) Bromocriptine reduces cigarette smoking. Addiction 95:1173\u20131183","journal-title":"Addiction"},{"key":"16_CR346","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1021\/ja00989a032","volume":"89","author":"KW Bentley","year":"1967","unstructured":"Bentley KW, Hardy DG (1967) Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J Am Chem Soc 89:3281\u20133292","journal-title":"J Am Chem Soc"},{"key":"16_CR347","first-page":"183","volume":"27","author":"G Rolly","year":"1976","unstructured":"Rolly G, Versichelen L (1976) Buprenorphine as postoperative analgesic. Acta Anaesthesiol Belg 27:183\u2013186","journal-title":"Acta Anaesthesiol Belg"},{"key":"16_CR348","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","volume":"35","author":"DR Jasinski","year":"1978","unstructured":"Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501\u2013516","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR349","first-page":"263","volume":"4","author":"HA Segu\u00ed","year":"2020","unstructured":"Segu\u00ed HA, Melin K, Qui\u00f1ones DS, Duconge J (2020) A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. J Transl Genet Genom 4:263\u2013277","journal-title":"J Transl Genet Genom"},{"key":"16_CR350","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/187152710790966678","volume":"9","author":"KS Barth","year":"2010","unstructured":"Barth KS, Malcolm RJ (2010) Disulfiram: an old therapeutic with new applications. CNS Neurol Disord Drug Targets 9:5\u201312","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"16_CR351","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1741-7015-9-119","volume":"9","author":"D Shorter","year":"2011","unstructured":"Shorter D, Kosten TR (2011) Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med 9:119","journal-title":"BMC Med"},{"key":"16_CR352","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00213-005-0139-8","volume":"183","author":"BN Bourdelat-Parks","year":"2005","unstructured":"Bourdelat-Parks BN, Anderson GM, Donaldson ZR, Weiss JM, Bonsall RW, Emery MS, Liles LC, Weinshenker D (2005) Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology 183:72\u201380","journal-title":"Psychopharmacology"},{"key":"16_CR353","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/sj.npp.1301000","volume":"31","author":"JR Schank","year":"2006","unstructured":"Schank JR, Ventura R, Puglisi-Allegra S, Alcaro A, Cole CD, Liles LC, Seeman P, Weinshenker D (2006) Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 31:2221\u20132230","journal-title":"Neuropsychopharmacology"},{"key":"16_CR354","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1360-0443.1998.9357137.x","volume":"93","author":"KM Carroll","year":"1998","unstructured":"Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ (1998) Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93:713\u2013727","journal-title":"Addiction"},{"key":"16_CR355","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","volume":"61","author":"KM Carroll","year":"2004","unstructured":"Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 61:264\u2013272","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR356","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1360-0443.2000.9522198.x","volume":"95","author":"IL Petrakis","year":"2000","unstructured":"Petrakis IL, Carroll KM, Nich C, Gordon LT, McCance-Katz EF, Frankforter T, Rounsaville BJ (2000) Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95:219\u2013228","journal-title":"Addiction"},{"key":"16_CR357","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0376-8716(98)00050-7","volume":"52","author":"EF McCance-Katz","year":"1998","unstructured":"McCance-Katz EF, Kosten TR, Jatlow P (1998) Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 52:27\u201339","journal-title":"Drug Alcohol Depend"},{"key":"16_CR358","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/0006-3223(94)00361-6","volume":"37","author":"FA Hameedi","year":"1995","unstructured":"Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR (1995) Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry 37:560\u2013563","journal-title":"Biol Psychiatry"},{"key":"16_CR359","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugalcdep.2006.08.016","volume":"87","author":"JR Baker","year":"2007","unstructured":"Baker JR, Jatlow P, McCance-Katz EF (2007) Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend 87:202\u2013209","journal-title":"Drug Alcohol Depend"},{"key":"16_CR360","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/10550499309115944","volume":"2","author":"KM Carroll","year":"1993","unstructured":"Carroll KM, Ziedonis D, O'Malley S, McCance-Katz E, Gordon L, Rounsaville B (1993) Pharmacologic interventions for alcohol- and cocaine-abusing individuals. Am J Addict 2:77\u201379","journal-title":"Am J Addict"},{"key":"16_CR361","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1176\/ajp.150.4.675b","volume":"150","author":"ST Higgins","year":"1993","unstructured":"Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F (1993) Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 150:675\u2013676","journal-title":"Am J Psychiatry"},{"key":"16_CR362","unstructured":"Kim J, Nguyen H (2021) Doxazosin. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island. Bookshelf ID: NBK557459"},{"issue":"8","key":"16_CR363","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1526-4637.2007.00325.x","volume":"9","author":"N Tsavaris","year":"2008","unstructured":"Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, Pagouni E, Pikazis D, Zis PV, Koufos C (2008) Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med 9(8):1209\u20131216","journal-title":"Pain Med"},{"issue":"3","key":"16_CR364","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00540-010-0913-6","volume":"24","author":"YC Arai","year":"2010","unstructured":"Arai YC, Matsubara T, Shimo K, Suetomi K, Nishihara M, Ushida T, Kobayashi K, Suzuki C, Kinoshita A, Kondo M, Matsubara S, Hayashi R, Tohyama Y, Nishida K, Arakawa M (2010) Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. J Anesth 24(3):407\u2013410","journal-title":"J Anesth"},{"key":"16_CR365","first-page":"201","volume":"3","author":"L Lemos","year":"2010","unstructured":"Lemos L, Fontes R, Flores S, Oliveira P, Almeida A (2010) Effectiveness of the association between carbamazepine and peripheral analgesic block with ropivacaine for the treatment of trigeminal neuralgia. J Pain Res 3:201\u2013212","journal-title":"J Pain Res"},{"issue":"1","key":"16_CR366","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/187152409787601932","volume":"9","author":"JH Vranken","year":"2009","unstructured":"Vranken JH (2009) Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 9(1):71\u201378","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"85","key":"16_CR367","first-page":"61","volume":"15","author":"B Paradowski","year":"2003","unstructured":"Paradowski B, Bilinska M (2003) Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus. Pol Merkur Lekarski 15(85):61\u201364","journal-title":"Pol Merkur Lekarski"},{"issue":"2","key":"16_CR368","first-page":"73","volume":"43","author":"WH Jean","year":"2005","unstructured":"Jean WH, Wu CC, Mok MS, Sun WZ (2005) Starting dose of gabapentin for patients with post-herpetic neuralgia\u2014a dose response study. Acta Anaesthesiol Taiwanica 43(2):73\u201377","journal-title":"Acta Anaesthesiol Taiwanica"},{"issue":"2","key":"16_CR369","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","volume":"94","author":"AS Rice","year":"2001","unstructured":"Rice AS, Maton S (2001) Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 94(2):215\u2013224. https:\/\/doi.org\/10.1016\/S0304-3959(01)00407-9","journal-title":"Pain"},{"issue":"3","key":"16_CR370","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12272-013-0057-y","volume":"36","author":"A Kukkar","year":"2013","unstructured":"Kukkar A, Bali A, Singh N, Jaggi AS (2013) Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res 36(3):237\u2013251","journal-title":"Arch Pharm Res"},{"issue":"8","key":"16_CR371","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/1060028015585849","volume":"49","author":"JG Leung","year":"2015","unstructured":"Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM (2015) The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother 49(8):897\u2013906","journal-title":"Ann Pharmacother"},{"key":"16_CR372","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/archinte.1948.00020040042004","volume":"82","author":"H Isbell","year":"1948","unstructured":"Isbell H, Wilker A, Eisenman AJ, Daingerfield M, Frank K (1948) Liability of addiction to 6-dimethylamino-4-4-diphenyl-3-heptanone (methadon, amidone or 10820) in man; experimental addiction to methadon. Arch Intern Med (Chicago, Ill.: 1908) 82:362\u2013392","journal-title":"Arch Intern Med (Chicago, Ill.: 1908)"},{"key":"16_CR373","first-page":"122","volume":"79","author":"VP Dole","year":"1966","unstructured":"Dole VP, Nyswander ME, Kreek MJ (1966) Narcotic blockade--a medical technique for stopping heroin use by addicts. Trans Assoc Am Phys 79:122\u2013136","journal-title":"Trans Assoc Am Phys"},{"key":"16_CR374","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/alcalc\/agt030","volume":"48","author":"A Thorsell","year":"2013","unstructured":"Thorsell A (2013) The mu-opioid receptor and treatment response to naltrexone. Alcohol Alcohol 48:402\u2013408","journal-title":"Alcohol Alcohol"},{"key":"16_CR375","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart G (2012) Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 31:207\u2013225","journal-title":"J Addict Dis"},{"key":"16_CR376","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 10","key":"16_CR377","first-page":"28","volume":"58","author":"FP Bymaster","year":"1997","unstructured":"Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA (1997) In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 58(Suppl 10):28\u201336","journal-title":"J Clin Psychiatry"},{"key":"16_CR378","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1345\/aph.1D191","volume":"38","author":"M Constenla","year":"2004","unstructured":"Constenla M (2004) 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother 38:1683\u20131691","journal-title":"Ann Pharmacother"},{"key":"16_CR379","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2165\/00003495-199447060-00009","volume":"47","author":"DH Peters","year":"1994","unstructured":"Peters DH, Faulds D (1994) Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 47:1010\u20131032","journal-title":"Drugs"},{"key":"16_CR380","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","volume":"67","author":"KA Lyseng-Williamson","year":"2007","unstructured":"Lyseng-Williamson KA, Yang LP (2007) Topiramate: a review of its use in the treatment of epilepsy. Drugs 67:2231\u20132256","journal-title":"Drugs"},{"key":"16_CR381","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","volume":"21","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD (2019) Current status of antiepileptic drugs as preventive migraine therapy. Curr Treat Options Neurol 21:16","journal-title":"Curr Treat Options Neurol"},{"key":"16_CR382","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11894-014-0394-0","volume":"16","author":"RT Hurt","year":"2014","unstructured":"Hurt RT, Edakkanambeth Varayil J, Ebbert JO (2014) New pharmacological treatments for the management of obesity. Curr Gastroenterol Rep 16:394","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 1","key":"16_CR383","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl 1):S3\u2013S9","journal-title":"Epilepsia"},{"key":"16_CR384","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284\u2013295. April 2022"}],"container-title":["Methods in Molecular Biology","Pharmacogenomics in Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2573-6_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T16:58:24Z","timestamp":1701017904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2573-6_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071625729","9781071625736"],"references-count":384,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2573-6_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"7 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}